index,Regulator Name,Regulator Type,Regulator Subtype,Regulator HGNC Symbol,Regulator Database,Regulator ID,Regulator Compartment,Regulator Compartment ID,Regulated Name,Regulated Type,Regulated Subtype,Regulated HGNC Symbol,Regulated Database,Regulated ID,Regulated Compartment,Regulated Compartment ID,Sign,Connection Type,Mechanism,Site,Cell Line,Cell Type,Tissue Type,Organism,Unnamed: 0,Score,Source,Statements,Paper IDs,Evidence Score,Match Score,Kind Score,Epistemic Value,Total Score
2812,rac1,protein,,rac1,uniprot,p63000,cytoplasm,go:0005737,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,d,association,,cos-7,fibroblast-like,kidney,human,['1526'],nan,nan,"we have shown previously that rac1 is directly associated with erk, but in an egf-independent manner [21]. in this study, we first examined whether rhoa also interacts with erk. we expressed gfp-rhoa in cos-7 cells by transient transfection. then, we immunoprecipitated (iped) gfp-rhoa and immunoblotted the immunoprecipitates with antibodies to erk and phosphorylated erk (p-erk). as shown in fig 1, erk was co-iped with gfp-rhoa with or without egf stimulation. however, the association of rhoa with p-erk was much stronger following egf stimulation, which could be due to the increase of p-erk in response to egf (fig 1a). we further examined the interaction between rhoa and erk by gst pull-down assay (fig 1b). total cell lysates from cos-7 cells, either treated with egf or not treated, were incubated with gst-rhoa. erk was associated with gst-rhoa with or without egf stimulation; however, the association between p-erk and gst-rhoa was only observed following egf stimulation (fig 1b). as a control, we showed that there is no association between erk or p-erk and gst (fig 1b).",pmc4729484,1,10,7,1,17
1766,mammalian target of rapamycin,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,p70s6 kinase (p70s6k),protein,,rps6kb1,uniprot,p23443,cytoplasm,go:0005737,positive,d,targeting,,,breast cancer cells,breast,human,['962'],nan,nan,"mammalian target of rapamycin is a downstream mediator of pi3k/akt signalling, regulating proliferation, survival, mobility, and angiogenesis via targeting p70s6 kinase (p70s6k) and 4e-bp1 in breast cancers that exhibit constitutively activated pi3k/akt signalling (bjornsti and houghton, 2004). accumulating evidence suggests that pi3k/akt/mtor promote breast cancer cell survival and resistance to chemotherapeutics such as trastuzumab (a blocking antibody to her-2) and tamoxifen (hynes and dey, 2009; ghayad et al, 2010). the mtor inhibitors rapamycin and rapamycin analogues (cci-779, rad001, and ap23573) have exhibited impressive growth inhibitory effects against a broad range of human cancers, including breast cancer, in preclinical and early clinical studies (chan, 2004; vignot et al, 2005). in this study, we demonstrate that α-tea functions as an mtor inhibitor, capable of suppressing mtor by decreasing constitutively activated mtor (phosphorylated status of mtor) and its downstream mediators p70s6k and 4e-bp1. in addition, our data show that α-tea not only enhances rapamycin suppression of mtor and induction of apoptosis, but also suppresses rapamycin-mediated feedback activation of akt, providing a rationale for developing a combination regimen of mtor+α-tea for breast cancer treatment.",pmc3039802,1,10,7,1,17
732,chk2,protein,,chek2,uniprot,o96017,,,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,d,phosphorylation,,,keratinocytes,,mouse,['560'],nan,nan,"chk2+/− throughout the g2 and g3 generations, thus in a setting where all chromosomes present progressively shorten telomeres. it is conceivable that the chk2-mediated response in g3 terc-deficient mice is masked by a compensatory induction of a chk2-independent mechanism that leads to p53/p21 activation. in fact, nalapareddy et al. detected significantly higher levels of phosphorylated chk1 in ig4 chk2−/− as compared to ig4 chk2+/+ (nalapareddy et al., 2010). in agreement with nalapareddy et al., we also detected a slight increase in chk1 phosphorylation in the absence of chk2 in trf1-deficient keratinocytes, which explains the fact that p53 levels were still elevated in chk2 cohorts compared to the wild-types. this fact also explains that chk2 deficiency only partially rescued survival and phenotypes associated to trf1 deficiency, while p53 deficiency was previously described by us to fully rescue trf1δ/δ",pmc4331747,1,10,7,1,17
768,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,prb,protein,,rb1,uniprot,p06400,nucleus,go:0005634,positive,d,phosphorylation,,,,,human,['46'],nan,nan,"chk2 also seems to impose cell cycle arrest through other pathways (figure 3b) whose relevance to the ddr is unknown. for example, chk2 phosphorylates prb which enhances the formation of the transcriptionally inactive prb/e2f-1 complex causing g1/s arrest and apoptosis repression (inoue et al., 2007). furthermore, chk2 phosphorylates the serine/threonine protein kinase lats2 probably inducing g1/s arrest (okada et al., 2011). three other additional mechanisms leading to g2/m arrest have been proposed. in the first, chk2 and atm phosphorylate the apoptosis antagonizing transcription factor che-1, which results in its stabilization and recruitment to the promoters of p21 and p53 genes after damage, leading to their transcription and to the sustainment of g2/m arrest (bruno et al., 2006). in the second, atm phosphorylates the serine/threonine kinase receptor-associated protein strap, a p53 cofactor, promoting its nuclear localization, whereas strap phosphorylation by chk2 augments its stability, inducing a p53-dependent g2/m arrest (adams et al., 2008). finally, chk2 phosphorylates and stabilizes the dual specificity protein kinase ttk/hmps1, promoting g2/m arrest by an unknown mechanism (yeh et al., 2009).",pmc4296918,1,10,7,1,17
2885,ras,protein,gtp-binding,ras,uniprot,p01112,plasma membrane,go:0005886,raf kinase,protein,kinase,raf1,uniprot,p04049,cytoplasm,go:0005737,positive,d,phosphorylation,,,,,human,['1622'],nan,nan,"oncolytic virus specifically replicate in cancer cells, but not in normal cells, by exploiting differences in the intracellular environment of tumor cell that promotes abnormal cell growth [1], [2], [3], [4]. constitutive activation of ras signaling was originally reported to be used by oncolytic reovirus to increase its replicative ability [5]. following the discovery of reovirus oncolysis, other viruses, such as wild type herpes simplex virus (hsv) [6], vesicular stomatitis virus (vsv) [4], influenza virus (delns1 strain) [7], adenovirus (vai mutant) [8], poliovirus [9], and newcastle disease virus [10] were found to similarly exploit activated ras signaling pathway for oncolysis. ras is a membrane bound gtp-binding protein that acts as a molecular switch to activate downstream pathways to regulate proliferation, differentiation and transformation [11]. in the canonical ras pathway, gtp-bound ras activates its downstream mediator, the raf kinase. activated raf then phosphorylates and activates the mek1/2 kinases, which phosphorylate and activate the extracellular signal-regulated kinase (erk) 1 and 2. erk1/2 can then activate or inhibit transcription factors to promote cell survival and proliferation [12]. activating mutations of ras have been found in approximately 30% of all human tumours [13]. moreover, in the absence of the active mutation of ras, ras pathway is often activated by inappropriately activation of its upstream signaling components, such as epidermal growth factor receptor, her2/neu and src [14].",pmc3436881,1,10,7,1,17
987,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,pi3k,protein,,pik3ca,uniprot,p42336,cytoplasm,go:0005737,positive,d,activation,,,,,human,['3616'],nan,nan,"the most frequently found alteration of the epidermal growth factor receptor (egfr) in human tumors is a deletion of exons 2-7. this receptor is termed egfrviii. high levels of pi3k activity were constitutively present in egfrviii-transformed cells and were dependent upon the kinase activity of the receptor. treatment with the pi3k inhibitors wortmannin and ly294002 blocked both anchorage-independent growth and growth in low serum media and also resulted in morphological reversion of egfrviii-transformed cells [47]. results from another study suggested that the constitutively active egfrviii can enhance cell proliferation in glioblastoma in part by down-regulation of p27(kip1) through activation of the pi3k/akt pathway [297]. erbb-2-overexpressing human mammary epithelial (hme) cells exhibit several transformed phenotypes including growth factor independence, anchorage-independent growth, motility, and invasiveness [298]. to identify pathways leading from pi3k to specific phenotypes, constitutively active akt or pten were expressed in erbb-2-overexpressing cells, or in hme cells [298]. hme cells expressing constitutively active akt were growth factor-independent, anchorage-independent and motile, but not invasive [298]. pten expression blocked erbb-2-mediated invasion but none of the other phenotypes [298]. this study concluded that a pi3k-dependent and p38mapk-dependent pathways lead to activation of akt, and activation of pkcδ, via pi3k, mediates invasion [298]. breast cancer cells over-expressing erbb2 depend on its activity for proliferation, because treatment of these cells with erbb2-specific antagonistic antibodies or kinase inhibitors blocks tumor cells in the g1 phase of the cell cycle. erbb3 is a partner for erbb2 in promoting cellular transformation [299]. loss of functional erbb2 or erbb3 had similar effects on cell proliferation and cell cycle regulators [299]. furthermore, expression of constitutively active akt rescued the proliferative block induced as a consequence of loss of erbb2 or erbb3 signaling [299]. these results demonstrated that erbb2 over-expression and activity alone are insufficient to promote breast tumor cell division. erbb3's role is to couple active erbb2 to the pi3k/akt pathway [299]. thus, the erbb2/erbb3 dimer functions as an oncogenic unit to drive breast tumor cell proliferation [299].",pmc2652403,1,10,7,1,17
2835,raf,protein,,raf1,uniprot,p04049,,,mek1,protein,,map2k1,uniprot,q02750,,,positive,d,phosphorylation,s/t residues,,,,,['1928'],nan,nan,"raf phosphorylates and activates the mitogen-activated protein kinase kinase-1 (mek1) (a dual specificity kinase (t/y) on s/t residues [1-4]). other proteins such as kinase suppressor of ras (ksr) have recently been shown to phosphorylate mek1 [44-48]. ksr has scaffolding properties and interacts with raf, mek and erk which regulate erk activation [44-48]. ksr can form dimers with various raf proteins which alter the effects of raf inhibitors. ksr1 competes with raf-1 for raf inhibitor-induced binding to b-raf which decreases the normal erk activation observed after raf-inhibitor treatment [47].",pmc3660063,1,10,7,1,17
989,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,ras,protein,,ras,uniprot,p01116,cytoplasm,go:0005737,positive,d,binding,,,,,human,['2674'],nan,nan,"the flow chart in figure 1 shows that the same key signal transducers are activated by both egfr and ir, either directly or indirectly. importantly, although either receptor can stimulate both the ras/erk and pi3k/akt pathways, the major routes of activation are different. ir phosphorylates irs proteins, which are linked to the activation of ras/erk pathway through binding to the grb2–sos complex (sos is a guanine nucleotide exchange factor for ras), whereas egfr activates the same pathway either by direct binding of grb2-sos or by binding and phosphorylation of shc, which then recruits the grb2–sos complex (white, 1998; sebastian et al, 2006). likewise, the pi3k/akt pathway is activated by ir via either direct or irs-mediated recruitment of pi3k, whereas egfr-mediated pi3k activation occurs mainly via a more intricate route that involves egfr- and src-induced phosphorylation of the grb2-associated binder 1 (gab1) (rodrigues et al, 2000; gu and neel, 2003; kiyatkin et al, 2006).",pmc2683723,1,10,7,1,17
1658,irs-1,protein,,irs1,uniprot,p35568,,,pi3k,protein,p85 subunit,pik3r1,uniprot,p27986,,,positive,i,association,,mefs,,,,['709'],nan,nan,"−/− mefs, irs-1 is both poorly tyrosine phosphorylated and associated with pi3k after stimulation of cells with insulin. rapamycin treatment for 1 h results in a partial restoration of both irs-1 tyrosine phosphorylation and association with the p85 subunit of pi3k in tsc2",pmc2172316,1,10,7,1,17
1670,jnk,protein,,mapk8,uniprot,p45983,cytoplasm,go:0005737,c-jun,protein,,jun,uniprot,p05412,nucleus,go:0005634,positive,d,phosphorylation,,,,,human,['190'],nan,nan,"between jnk activation and c-jun phosphorylation (16). therefore, this dual",pmc3084876,1,10,7,1,17
1704,kras,protein,mutant tumor biomarker,kras,uniprot,p01116,cytoplasm,go:0005737,raf,protein,,raf1,uniprot,p04049,cytoplasm,go:0005737,positive,d,interacting,,,,nsclc tumors,human,['2663'],nan,nan,"overall, our results have a number of general implications. we have defined the mechanism of mutant tumor biomarker (kras)-mediated shifting signaling inhibitory effect of gefitinib through kras interacting with pi3k or raf. we design a therapeutic schedule of atorvastatin plus gefitinib, which could effectively exert a cytotoxic effect on the kras mutant nsclc tumors under various conditions and more substantially prolong the survival rate in preclinical study.",pmc3789171,1,10,7,1,17
1786,mdm2,protein,,mdm2,uniprot,q00987,nucleus,go:0005634,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,negative,d,binds,,ls8817,epithelial,,human,['1016'],nan,nan,"to identify which domains of mdm2 were necessary to suppress senescence we expressed different mutant alleles of mdm2 and scored their effect in pd0332991 treated ls8817 cells. the v75a mutant disrupts binding to p53 [31]. the c464a mutant eliminates e3 ligase activity by disrupting the cross brace structure of the ring [32]. the i440a, l468a, or p476a mutants also eliminate e3 ligase activity but do so by selectively disrupting e2 binding [33]. the δ254-264 mutant allele in the acidic domain disrupts multiple mdm2 protein interactions [34]. of these only the v75a mutant was capable of suppressing the pd0332991-induced accumulation of sa-β-gal positive cells (figure 3d). another mutant that overlaps with the ring but also affects nucleolar localization (δ464-471) could not suppress accumulation of sa-β-gal positive cells. this indicated that mdm2's ability to suppress pd0332991-induced senescence required its e3 ligase activity and the acidic domain but was independent of its ability to bind to p53.",pmc4480747,1,10,7,1,17
2905,ras,protein,,,uniprot,p01112,plasma membrane,go:0005886,braf,protein,,braf,uniprot,p15056,cytoplasm,go:0005737,positive,d,activation,,,,,human,['3245'],nan,nan,"ras and raf [54], erk kinases are commonly activated abnormally in most human cancers due to the converging site in transmitting signals derived from growth factors. the amplification of upstream growth factor receptors takes place frequently in cancer, including the epidermal growth factor receptor (egfr) in solid tumors [87] and bcr-abl [fusion of the abl1 oncogene gene on chromosome 9 to the bcr (breakpoint cluster region) gene on chromosome 22] in chronic myeloid leukemia (cml) [88]. additionally, the amplification of the ras oncogene is detected in approximately 30% of human cancers [89]. mutations leading to the activation of braf (the b isoform of raf) were detected in 27-70% of melanoma, 36-53% of papillary thyroid cancer, 5-22% of colorectal cancer, and 30% of ovarian cancer [90]. in line with abnormal activation of the erk kinases being one of the common events in human cancers, erk kinases are well regarded to drive cancerous cell proliferation and promote other oncogenic events, including survival and angiogenesis [91, 92]. therefore, inhibition of mek-mediated erk activation may be an effective option in cancer therapy. indeed, several highly specific mek inhibitors have been developed, including pd184352/ci-1040 (pfizer), pd0325901 (pfizer), azd6244 (arry-142886 or selumetinib) (astra zeneca) and rdea119 (ardea biosciences) [93]. while these small molecule mek inhibitors are highly specific and effective in preclinical settings, they are, however, not effective in clinical trials on a variety of tumors. pd184352, the first mek inhibitor entering clinical trials, failed to show encouraging results when treating patients with advanced non-small cell lung, breast, colon, and pancreatic cancer [94]. pd0325901 also did not produce overwhelming positive outcomes in clinical trials on patients with breast, colon, melanoma, and non-small cell lung cancer (nsclc) [95, 96]. this was also the situation for a newly developed mek inhibitor azd6244 when examined in clinical trials on melanoma and nsclc [97, 98]. while better designed clinical trials on selected patients with tumors that are dictated to erk activation caused by braf or kras activation [99, 100], might have yielded more positive outcomes, it is uncertain how the potential positive results might be. this is because 1) in clinical trials on melanoma, only 12% of tumors with braf mutations were partially responsive to azd6244 [97], 2) nsclcs with kras mutations display heterozygous responses to mek inhibitors, and 3) a minor proportion (21%) of patients having braf v600 mutation showed responses to the mek inhibitor gsk1120212 [101, 102]. taken together, clinical trials using a variety of mek inhibitors were unable to produce outcomes that are proportional to the prevalence of erk activation in human cancers.",pmc3330700,1,10,7,1,17
87,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,autophagy,process,,,,,cytoplasm,go:0005737,negative,d,knockdown,,achn,renal carcinoma,kidney,human,['2616'],nan,nan,knockdown of akt reduces the magnitude of autophagy induction in achn cells,pmc4720880,1,10,7,1,17
1975,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,p70 s6 kinase,protein,,rps6kb1,uniprot,p23443,cytoplasm,go:0005737,positive,d,phosphorylation,,,not specified,not specified,not specified,['2829'],nan,nan,"one of the substrates of mtor is the p70 s6 kinase (p70s6k) which upon phosphorylation by mtor is activated. studies have shown that p70s6k- elicited phosphorylation of the insulin receptor substrate 1 (irs-1) results in inhibition of irs-1 binding to the insulin or insulin like growth factor (igf-i) receptors or degradation of irs-1 (harrington et al., 2004; manning, 2004; um et al., 2004). in this manner, mtor via p70s6k can inhibit insulin or igf-i receptor- mediated prosurvival and proliferative signaling. thus, rapamycin- induced inhibition of mtor and, therefore, suppression of p70s6k activity alleviates the “negative feed-back” inhibition of irs-1 and results in increased irs-1 protein levels to further activate akt by augmenting igf-i receptor signaling. indeed, the antitumorigenic action of rapamycin in breast and colon cancers has been shown to be decreased due to increased akt activation (wan et al., 2007). these studies suggest the presence of compensatory mechanism(s) in rapamycin-induced apoptotic process. other than the possible role of a compensatory increase in akt pathway in response to rapamycin, there is a paucity of information on how other mechanisms activated by rapamycin may decrease sensitivity to the drug.",pmc2653860,1,10,7,1,17
2016,mtor,protein,,mtor,uniprot,p42345,,,p70s6k,protein,,rps6kb1,uniprot,p23443,,,positive,d,phosphorylation,,lg-urca,,,,['2814'],nan,nan,"western blot analysis for mtor pathway protein expression in lg-urca cell lines and the antiproliferative effect of rapamycin in rt4 and 253j cells. (a) cell extracts from four urca cell lines (rt4 and 263j) were subjected to immunoblotting using antibodies directed against mtor, p-mtor, p70s6k and p-p70s6k. protein loading was normalized using an antibody recognizing β-actin. rt4 and 253j cells expressed phosphorylated mtor and p70s6k proteins. blots representative of three separate experiments are shown. (b) incubating rt4 and 263j cells with increasing doses of rapamycin demonstrated a dose-dependent reduction in cell proliferation at 3 days after treatment (r = −0.850, p < 0.001 in rt4 and r = -0.835, p < 0.001 in 253j cells).",pmc4104092,1,10,7,1,17
2028,mtor,protein,,,uniprot,p42345,cytoplasm,go:0005737,autophagy,process,,,,,cytoplasm,go:0005737,negative,d,inhibits,,,,,,['2602'],nan,nan,"on the basis of distinct cell morphology, three major types of cell death have been described: apoptosis, autophagic cell death, and programmed necrosis.1, 2, 3 accumulating evidence suggests the existence of several molecular connections among apoptosis, necrosis, and autophagy.3, 4 macroautophagy (hereafter called autophagy), an evolutionarily conserved catabolic and intracellular membrane trafficking process, is involved in the delivery of cytoplasmic contents and organelles to lysosomes for degradation.5 in general, the mammalian target of rapamycin (mtor) is a negative regulator of autophagy.6, 7, 8 as a member of the pi3k-related kinase family, mtor has been detected in two distinct complexes, mtorc1 and mtorc2, which regulate many aspects of cellular functions.9, 10 mtorc2 activates akt (protein kinase b), while pi3k/akt primarily activates mtorc1.11 once activated by akt, mtorc1 elicits a negative feedback loop to inhibit the activity of akt. mtorc1 phosphorylates two main substrates, ribosomal protein s6 kinase 1 (s6k1) and eukaryotic initiation factor 4e-binding protein 1 (4e-bp1).12",pmc4720880,1,10,7,1,17
2045,mtor,protein,,,uniprot,p42345,,,p70s6 kinase,protein,,rps6kb1,uniprot,p23443,,,positive,d,phosphorylation,ser371,,,bladder,human,['2221'],nan,nan,"the high grade human bladder cancer cell line ku-7 engineered to stably express firefly luciferase and green fluorescent protein (ku-7-luc) was provided by dr. h.k. seo (national cancer center, goyang, korea) and purchased from caliper life sciences (hopkinto, ma, usa). ku-7-luc was cultured in a roswell park memorial institute medium (rpmi 1640; gibco, grand island, ny, usa), supplemented with 10% fetal bovine serum (fbs). the media contained 50 µg/ml gentamycin sulfate. the ku-7-luc cell line was maintained at 37℃ in 5% co2. rapamycin was purchased from sigma (st. louis, mo, usa) and antibodies were purchased from different manufacturers: mtor, phophrylated mtor (p-mtor, ser 2448), p70s6 kinase (p70s6k), p-p70s6k (ser371), 4e-bp1, p-4e-bp1, eif4e, and p-eif4e (ser209) were obtained from cell signaling (beverly, ma, usa), while β-actin was obtained from sigma.",pmc4330487,1,10,7,1,17
2046,mtor,protein,,,uniprot,p42345,,,s6k1,protein,p70s6k,rps6kb1,uniprot,p23443,,,positive,d,activation,,,,,,['3063'],nan,nan,"the ribosomal protein s6 kinases are also important substrates of mtor. s6k1 (p70s6k; the better characterised s6 kinase) is implicated in the positive regulation of cell growth and proliferation (fumagalli and thomas, 2000). interestingly, s6k1 activation correlates with enhanced translation of a subset of mrnas that contain a terminal 5′ oligopyrimidine tract (top mrnas) (fumagalli and thomas, 2000). these mrnas encode ribosomal proteins, elongation factors, the poly-a binding protein and other components of the translational machinery that become selectively translated in response to growth factors. however, top mrna translation remains intact even when both s6k1 and s6k2 genes are genetically disrupted in mice (pende et al, 2004), indicating that s6ks are not essential for the regulation of top mrna translation.",pmc2361102,1,10,7,1,17
2053,mtor,protein,serine/threonine kinase,mtor,uniprot,p42345,cytoplasm,go:0005737,p70 ribosomal s6 kinase 1 (s6k1),protein,,rps6kb1,uniprot,p23443,cytoplasm,go:0005737,positive,d,phosphorylation,,,,,mammalian,['2240'],nan,nan,"mammalian target of rapamycin (mtor) is a serine/threonine kinase that belongs to the pi3k family. it can regulate an array of cellular functions including protein synthesis, metabolism, and cell proliferation. mtor has been shown to form two distinct complexes with different functions [11]: mtor complex 1 (mtorc1) and mtor complex 2 (mtorc2). mtorc1 is composed of mtor, raptor, pras40 and mlst8/gbl. it has two well-defined substrates: p70 ribosomal s6 kinase 1 (referred to s6k1) and 4e-bp1, both can regulate protein synthesis [12]. the critical functions of mtorc1 include dna double-strand break repair [13] and mitochondria function [14–19], and mtorc1 itself can play a negative feedback role in the pi3k/akt/mtor pathway via activation of its substrate, s6k1 that controls the signal influx by inhibiting the receptors when it is activated [20–23]. therefore, the feedback system can down-regulate protein synthesis to control cell proliferation. the second complex, mtorc2, is composed of mtor, rictor, msin1, protor, and mlst8 able to phosphorylate akt, an upstream regulator of mtorc1, to control the signaling pathway [24], suggesting a across-talk between mtorc1 and mtorc2. mtorc2 has also been indicated in the control of cellular metabolism in glioblastoma via c-myc regulation [25].",pmc4373728,1,10,7,1,17
2085,mtorc1,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,pras40,protein,,akt1s1,uniprot,o95269,nucleus,go:0005634,positive,d,interaction,nuclear export,"hela, u2os",cancer,,human,['2288'],nan,nan,"although other negative regulators of mtorc1 such as tsc1/2 and lkb1 function as tumor suppressors, pras40 has a pro-tumorigenic function and is positively correlated with proliferative disease progression.29, 31 to clarify the tumorigenic function of pras40 we have interrogated its subcellular localization and interactome. here we experimentally demonstrate that pras40 subcellular distribution is controlled at least in part by crm1-dependent nuclear export directed by a nes sequence - 218iaasmralvl227. these results, which were obtained in the human cancer cell lines hela and u2os, are consistent with findings in a14 mouse fibroblasts published during the preparation of this manuscript.44 interestingly, pras40 contains neither a classical nls (cnls)48 nor a nucleolar localization signal.49, 50 although the mw of pras40 may be low enough to allow nuclear entry via passive diffusion, gel filtration analyses indicate that pras40 exits in high mw complexes in cells. therefore, we speculate that pras40 may be actively imported to the nucleus either through interaction with a cnls-containing protein or in a manner dependent upon a non-classical nls.51",pmc4216640,1,10,7,1,17
2088,mtorc1,protein,,,uniprot,,cytoplasm,go:0005737,p70s6k,protein,,,uniprot,p23443,cytoplasm,go:0005737,positive,d,regulation,,,,,,['2016'],nan,nan,"gsk-3 can regulate this pathway by phosphorylation of s371 on p70s6k [61,62,65,186,187]. gsk-3 interacts with mtorc1 to regulate p70s6k activity [61,62]. gsk-3beta can have negative effects on p70s6k activity [188]. gsk-3 can phosphorylate tsc2 which results in inhibition of mtorc1 and prevents the phosphorylation of p70s6k at t389 [189,190]. little is known about the interactions of gsk-3 and mtorc2 in oncogenesis. mtorc2 stabilizes cyclin d1 through prevention of gsk3- dependent and fbx4-mediated cyclin d1 degradation [190] thursday",pmc4102778,1,10,7,1,17
456,c-flip,protein,,cflar,uniprot,q13158,,,caspase-8,protein,,casp8,uniprot,q14790,,,positive,d,cleavage,,pc-3,,,human,['2164'],nan,nan,"further, to rule out whether the bid cleavage observed upon 3-awa treatment was due to c-flip-dependent cleavage of caspase-8 or by some other mechanism, pc-3 cells were transfected with c-flip sirna or treated with 3-awa in presence/absence of z-vad. the caspase-8 cleavage was robustly enhanced in the c-flip sirna and 3-awa treated cells as compared to dmso, control sirna and 3-awa plus z-vad treated cells (fig. 4e,f). the aim to analyze the expression of truncated bid (t-bid) was to emphasize the activation of both extrinsic and intrinsic apoptotic pathways by 3-awa following the translational block. despite the anti-proliferative potency of 3-awa has already been described in our previous studies1314, however, for further support a study of 3-awa on cell cycle was carried out. the results depicted that 3-awa arrested the cells in g1 stage of the cell cycle (supplementary fig. s4a). additionally to cross-check whether the change in expression or activation of eif4e is independent/dependent of any apoptotic cue, the effect of 3-awa on eif4e in presence of z-vad was examined. it was found that the effect of 3-awa in context to the activation/expressional changes in eif4e were consistent (supplementary fig. s4c), implying that eif4e regulation due to 3-awa treatment is independent of cell death and may act as a driver to turn on apoptosis. to further check whether any putative connection existed due to 3-awa driven reduction in c-flip with fas expression and trafficking, we monitored the expression and trafficking of fas through immunocytochemistry both in 3-awa treated and c-flip sirna transfected pc-3 cells. surprisingly, the results showed a sharp increase in the expression and trafficking of fas in c-flip sirna transfected and 3-awa treated cells (fig. 4g).",pmc4700468,1,10,7,1,17
2439,p70s6kinase,protein,s6k1,rps6kb1,uniprot,p23443,cytoplasm,go:0005737,irs-1,protein,,irs1,uniprot,p35568,cytoplasm,go:0005737,negative,d,phosphorylation,"s1101, s270",,,,human,['1270'],nan,nan,"p70s6kinase (s6k1) is a member of the ribosomal s6 kinase family that plays an important role in cell proliferation, cell cycle progression, cell size, and gene translation. it is well documented to be upregulated in many tissue types and markedly so in colorectal tumors 36. the main upstream activator of p70 s6 kinase is mammalian target of rapamycin (mtor) via the pi3k-akt signaling pathway. it is specifically mtorc1 that has been demonstrated to interact with p70 s6 kinase, phosphorylating t421/s424 and t386 regulating various downstream responses. the most direct of these responses is its activation of rps6 and subsequent increased protein translation. this of course results in increased proliferation, growth, and survival. however, as stated previously, p70 s6 kinase has an alternate pathway that it may orchestrate. insulin signaling has been shown to be negatively regulated via irs-1 inhibition as a direct result of an akt/mtorc1/p70 s6 kinase pathway. p70 s6 kinase directly binds to and phosphorylates irs-1 via two different serine residues, s1101 and s270. upon binding, irs-1 activity has been shown to be decreased, which is associated with an increase in s636 phosphorylation of irs-1. our data shows that p70 s6 kinase is also significantly increasing in its phosphorylation state across stages i to iii, and ii to iii, but decreasing between stages iii to iv (fig. 3). given the interaction of p70 s6 kinase and irs-1, this data strengthens our argument that the negative regulation of insulin signaling in crc remains intact. the increases observed between stages i to iii and ii to iii are in good agreement with the above argument however the decrease observed between stages iii to iv require further consideration. what is striking is that molecules known to be interacting within the insulin signaling pathway are phosphorylated in accordance with each other. as we observe the increases in p70s6 kinase and highlight the inhibition of irs-1 we see an appropriate increase in irs-1 s636 phosphorylation and as we observe a decrease in p70s6 kinases between stages iii to iv we also see, albeit not significant, a decrease in irs-1 phosphorylation between the same stages. an argument could be made where there is a switch that is engaged at the later stages of crc where negative regulation of the igf-1r pathway is no longer supported and evasion of apoptosis and increased protein translation are forgone for an increase in cell growth and differentiation. (see fig. 2)",pmc3187934,1,10,7,1,17
207,akt,protein,,,uniprot,p31749,,,mdm2,protein,,mdm2,uniprot,q00987,,,positive,d,phosphorylation,,,,,human,['380'],nan,nan,"akt has been reported to phosphorylate and activate mdm2 leading to de-stabilization of p53 [58, 59]. similarly we find that inhibition of akt in arf null mcf7 cells leads to the stabilization of p53 (fig. s3g). however, re-expression of arf appears to be dominant over akt mediated control of mdm2 activity (fig. s3g). to assess if inhibition of akt and regulation of arf localization represented a general mechanism of regulating p53mut stability we examined p53 expression in a range of cell lines from different histopathological origins, with wild type and p53 mutations, following treatment with pi-103. short term treatment with pi-103 reduces the levels of phospho-s48-npm and is accompanied with a rapid decrease of p53 levels in sq20b (fig. s5c). after 16 hr exposure to pi-103 a reduction in p53 stability is seen in all cells except arf null a549, panc1 and arf methylated lovo cells (fig. s5c and 6d).",pmc4171619,1,10,7,1,17
3055,s6k1,protein,,rps6kb1,uniprot,p23443,,,irs-1,protein,,irs1,uniprot,p35568,,,negative,d,inhibition,,,,,mefs,['687'],nan,nan,"−/− mefs. left, β-actin; right, irs-1. a single graph from triplicate determinations showing identical results is shown. (d) rnai-mediated inhibition of s6k1 and s6k2. western blotting of extracts from tsc2",pmc2172316,1,10,7,1,17
406,bcl-2,protein,pro-survival,bcl2,uniprot,p10415,,,beclin-1,protein,,becn1,uniprot,q14457,,,negative,d,binding,beclin-1,,,,,['3497'],nan,nan,"pro-survival bcl-2 family proteins negatively regulate autophagy by binding to beclin-1, which plays an important role in autophagosome formation through forming complexes with phosphatidylinositol 3-kinase catalytic subunit type 3 (pik3c3)/mammalian vacuolar protein sorting 34 homologue (hvps34) that is a nutrient-regulated lipid kinase [14, 16, 22]. binding of bcl-2, bcl-xl, or mcl-1 with beclin-1 interferes with the association of beclin-1 with pik3c3/hvps34 thus inhibiting its autophagy-inducing potential [14, 16, 23]. beclin-1 is a bh3-only protein and its association with pro-survival bcl-2 family proteins is competitively inhibited by other bh3-only proteins of the bcl-2 family [14, 16]. therefore, anti-survival bh3-only bcl-2 family proteins can activate autophagy through freeing beclin-1. in this regard, it is of note that binding of bh3-only proteins to pro-survival bcl-2 proteins is highly selective [24]. for example, while bim can bind to all pro-survival proteins of the family, noxa can only bind to mcl-1 and a1 [24].",pmc4294377,1,10,7,1,17
3047,s6k,protein,,rps6kb1,uniprot,p23443,,,irs-1,protein,,irs1,uniprot,p35568,,,negative,d,blocks,,,,,,['712'],nan,nan,s6k phosphorylation blocks irs-1 function. (a) irs-1 tyrosine phosphorylation and association with pi3k is suppressed in tsc2,pmc2172316,1,10,7,1,17
218,akt,protein,serine-threonine kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,akt,protein,serine-threonine kinase,akt1,uniprot,p31749,nucleus,go:0005634,positive,d,phosphorylation,ser473,,bronchial epithelium,lung,human,['416'],nan,nan,"the serine-threonine kinase akt is a central regulator of cell survival and apoptosis that is itself activated by phosphorylation. antibodies that specifically recognize the phosphorylated form (ser 473) were used to identify the phosphorylated, and thus activated, form of akt. intensity of staining was scored on a scale of 0 for negative, 1 for predominantly faint staining, 2 for predominantly moderate staining and 3 for predominantly strong staining. in normal bronchial epithelium, phospho-akt staining typically consisted of faint cytoplasmic stain with occasional cells staining with a more intense nuclear pattern (figure 1a). in some biopsies, there was a concentration of staining at the apical surface of the epithelium. the underlying interstitial cells were predominantly negative. with increasing pathological grade, there was an overall increase in the intensity of phospho-akt staining (figure 1) and an increase in the ihc score (figure 2a). as pathology grade increased to mild, moderate and severe dysplasia, there were also an increased number of cells with nuclear staining for phospho-akt (figure 1b,1c and 1d) in addition to an increase in cytoplasmic staining intensity (analysis of variance analysis using the kruskal-wallis chi-square test, p = 0.018). in addition, pairwise comparisons using the non-parametric mann-whitney rank-sum test indicated that staining intensity of the mild/moderate dysplasia and severe dysplasia/cis groups were significantly increased compared to normal (p = 0.02 and 0.004, respectively). similar to what has been previously reported [12], invasive carcinoma had a lesser degree of staining than advanced pre-neoplastic lesions (figure 2a). in squamous cell carcinomas, several tumors had intense plasma membrane associated staining for phospho-akt (figure 3a), while an antibody that recognized both phosphorylated and unphosphorylated akt showed equal staining throughout the cytoplasm and nucleus (figure 3b).",pmc1325242,1,10,7,1,17
3050,s6k1,protein,kinase,rps6kb1,uniprot,p23443,cytoplasm,go:0005737,irs-1,protein,,irs1,uniprot,p35568,cytoplasm,go:0005737,negative,d,phosphorylation,ser302,mefs (mouse embryonic fibroblasts),fibroblast,,human,['726'],nan,nan,"−/− mefs, the major kinase responsible for phosphorylating irs-1 ser302 is s6k1 and that phosphorylation of this site may disrupt the ability of the ptb domain to interact with activated insulin receptors. reversal of this phosphorylation by short-term treatment with rapamycin, or inhibition of s6k1 by rnai, partially rescues activation of pkb, arguing that phosphorylation by s6k may be a major mechanism to inactivate irs-1 function. however, the extent of the band shift we observe in both irs-1 and irs-2 extracted from tsc2-deficient cells might suggest that more than one site is phosphorylated by s6k (or perhaps other mtor-regulated kinases) in vivo; our data support the argument that the direct phosphorylation of the ptb domain site could account for the profound inhibition of irs-1 function in these cells. giraud et al. (2004) have also reported that irs-1 is phosphorylated at ser302, by an unidentified nutrient- and rapamycin-sensitive kinase. however, using a ser302-alanine mutant in 32d cells, these workers report that ser302 phosphorylation may be necessary for association with pi3k p85 and for a restricted set of insulin–pi3k-regulated responses including activation of s6k and dna synthesis. surprisingly, their work indicates that activation of pkb is largely unaffected by preventing phosphorylation at this site, suggesting that pip3 generation is unaffected by preventing ser302 phosphorylation. however, they did not examine the consequences upon insulin signaling of a phosphomimic of ser302 (which may reflect the situation occurring upon activation of mtor/s6k signaling reported here), rendering it difficult to determine what the consequences of increased phosphorylation of this site may be. however, our finding that regulation of irs by s6k occurs by both long-term (transcriptional) and acute (phosphorylation) mechanisms, and that both these mechanisms act in the same manner (i.e., inhibitory) toward insulin–pi3k activation, is consistent with what we observe in tsc2",pmc2172316,1,10,7,1,17
3051,s6k1,protein,,rps6kb1,uniprot,,,,irs-1,protein,,irs1,uniprot,,,,negative,i,,,,,,,['689'],nan,nan,"−/− treated with 20 nm rapamycin or rnai to s6k1 or s6k2. left, β-actin; right, irs-1. a single graph from triplicate determinations showing identical results is shown.",pmc2172316,1,10,7,1,17
167,akt,protein,,akt1,uniprot,p31749,,,mdm2,protein,,mdm2,uniprot,q00987,,,positive,d,promote,nucleolus,t24,,,human,['378'],nan,nan,"since inhibition of akt promotes arf localization to the nucleolus and enhanced mdm2 activity, we wished to address what effect increased mdm2 activity has on endogenous p53. upon inhibition of akt we observe a decrease in the level of endogenous p53 in t24 cells (fig. 4b). we were particularly intrigued as t24 cells express p53mut (in-frame deletion of tyr126). since mdm2 can degrade p53mut",pmc4171619,1,10,7,1,17
310,arf,protein,,cdkn2a,uniprot,p42771,nucleolus,go:0005730,mdm2,protein,,mdm2,uniprot,q00987,cell nucleus,go:0005634,negative,d,association,nucleolus,npm−/− mefs,fibroblast,,mouse,['374'],nan,nan,"to first confirm that a tripartite npm/arf/mdm2 complex exists in the soluble non-nucleolar fraction, a two-step co-immunoprecipitation was performed of flag labelled npm-wt, s48a and s48e from npm−/− mefs lysates. npm complexes were eluted using flag peptide and subsequent npm-mdm2 complexes isolated by immunoprecipitation of endogenous mdm2 from the flag elute. the presence of arf in npm-mdm2 complex pool reveals that a tripartite complex exists and, although differential stability of the flag-npm derivatives make comparisons of levels difficult, this appears independent of the akt mediated phosphorylation (fig. 4a). next we wanted to determine whether the effect of akt phosphorylation on npm oligomer formation and arf localisation affects the ability of npm-arf to associate with mdm2. in t24 cells we find an endogenous association of mdm2 with arf (fig. 4b and 4c) and also correlates with the low levels of basal mdm2 auto-ubiquitin ligase activity (fig. 4d). upon inhibition of akt with either pi-103 or mk-2206 we observe that the composition of the arf complexes shifts to exclude mdm2 with a concomitant increase in the apparent association of npm with arf due to higher stability (fig. 4c and s4b). loss of mdm2 from the npm/arf complex was concurrent with incorporation of npm into oligomers within the nucleolus and accumulation of arf nucleolar foci (fig. 3b, 4b and 4c).",pmc4171619,1,10,7,1,17
148,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,tsc2,protein,,tsc2,uniprot,p49815,cytoplasm,go:0005737,negative,d,phosphorylation,,,,,,['1948'],nan,nan,"tsc2 phosphorylation by akt represses gap activity of the tsc1/tsc2 complex, allowing rheb to accumulate in a gtp-bound state. rheb-gtp then activates, through a mechanism not yet fully elucidated, the protein kinase activity of mtor which complexes with raptor (regulatory associated protein of mtor) adaptor protein, dep domain containing mtor-interacting protein (deptor) and mlst8, a member of the lethal-with-sec-thirteen gene family, first identified in yeast, fk506 binding protein 38 (fkbp38) and proline-rich akt substrate 40 kda protein (pras40) [134-138]. raptor has also recently been shown to have other roles, including interactions with the rdna transcriptional apparatus in the nucleoli [189].",pmc3660063,1,10,7,1,17
311,arf,protein,,,,,nucleolus,,mdm2,protein,,mdm2,uniprot,q00987,nucleoplasm,go:0005654,negative,d,sequestering,nucleolus,,tumor cells,,,['396'],nan,nan,"although arf has long been recognized as an inhibitor of mdm2 [21, 22], debate exists regarding the cellular location and mechanism of arf mediated mdm2 inhibition. arf has been reported to promote p53 stability by sequestering mdm2 to the nucleolus [79, 80], whereas others have reported that nucleoplasmic arf suppresses mdm2 activity [46-48, 81]. our data argues for a model whereby mdm2 is inhibited by a nucleoplasmic pool of npm associated arf (fig. 4 and 5). oligomerisation of npm promotes accumulation of arf at the nucleolus but appears incompatible with mdm2 association (fig. s2b and 4). in agreement with this model, overexpression of npm and sequestration to the nucleolus has been proposed as mechanism whereby tumor cells inactivate and stabilize arf [41, 48, 57, 81],",pmc4171619,1,10,7,1,17
3185,src,protein,,,uniprot,,,,p38,protein,,mapk14,uniprot,q16539,,,positive,i,phosphorylation,,,,,human,['2148'],nan,nan,"we have demonstrated that src is involved in ep2-induced p38 phosphorylation (fig. 3a and b). consistent with our finding, src has been suggested to be involved in p38 activation during egf-induced vegf production in pancreatic cancer cells (summy et al., 2005) and in lysophosphatidic acid-mediated p38 activation (estrella et al., 2007). however, the mechanism by which src induces phosphorylation of p38 remains to be determined. we examined if ep2-induced p38 phosphorylation involves egfr pathway because src interacts with egfr. however, treatment with ag1478, a potent egfr kinase inhibitor, did not affect ep2-induced p38 phosphorylation and overexpression of egfr marginally affected p38 phosphorylation compared to src (data not shown), suggesting that ep2-induced p38 phosphorylation does not involve egfr pathway. phosphorylation of p38 is subject to kinase cascades and mkk3 or mkk6 are the main mkks that activate p38 (derijard et al., 1995; raingeaud et al., 1996). however, other possible mechanisms have been suggested for activation of p38 such as an interaction of p38 with tab-1 (transforming growth factor-activated kinase 1 binding protein 1) (ge et al., 2002) and conformational change due to phosphorylation at tyr323 (salvador et al., 2005). whether src directly phosphorylates p38 or activates other intermediate kinase for p38 is not clear.",pmc4624070,1,10,5,1,15
2603,pi3k,protein,,pik3ca,uniprot,p42336,,,akt,protein,,akt1,uniprot,p31749,,,positive,i,mediates,,,,,,['3595'],nan,nan,"the involvement of pi3k in prevention of apoptosis by polypeptide growth factor receptors was first described by studies using both wortmannin and ly294002 [168-170]. experiments with pharmacological inhibitors, as well as expression of wild-type and dominant-inhibitory forms of akt, demonstrated that akt mediates pi3k-dependent survival [171-175]. these findings were supported by studies showing that ras activation of pi3k suppresses c-myc-induced apoptosis through the activation of akt but not p70(s6k) [176]. uv-b light-induced-apoptosis was also prevented by igf-i/pi3k/akt signaling [177] and interleukin-3-dependent survival of hematopoietic cells required pi3k/akt signaling [178]. neuronal survival in the absence of nerve growth factor (ngf) was promoted by pi3k/akt [179] and it was also shown that akt can transduce a survival signal for differentiating neuronal cells through a mechanism that is independent of induction of bcl-2 or bcl-xl, or inhibition of jnk activity [180]. pi3k acting through akt was implicated as a key mediator of the aberrant survival of ras-transformed epithelial cells in the absence of attachment, and as a mediator of matrix-induced survival of normal epithelial cells [181].",pmc2652403,1,10,5,1,15
156,akt,protein,,akt1,uniprot,p31749,,,akt,protein,,akt1,uniprot,p31749,,,positive,i,upregulated,,,,,,['1970'],nan,nan,"akt is often upregulated in cancer cells and its overexpression is associated with a poor prognosis. increased expression of akt can result from activating pik3ca mutations, elimination or decrease in pten activity or elevated pkc-epsilon expression. elevated akt expression has also been associated with the pathology of pancreatic, glioma and prostate cancers [363-368].",pmc3660063,1,10,5,1,15
3378,tsc1,protein,,tsc1,hgnc,12470,,,mtorc1,protein,,mtorc1,,,,,negative,i,activates,,,,,,['1951'],nan,nan,"as stated previously, tsc1 and tsc2 have important roles in the regulation of mtorc1. an additional molecule important in this regulation is the liver kinase b (lkb1 also known as stk11). lkb1 is an important tumor suppressor and gatekeeper mutations of lkb1 cause the rare peutz-jeghers syndrome (pjs) which is a cancer-prone syndrome [191]. lkb1 is a gatekeeper gene and mutations in lkb1 are involved in the formation of hamartomatous polyps in pjs patients. lkb1 is an upstream activator of 5'amp-activated protein kinase (ampk) which activates tsc2 that negatively regulates mtorc1 [192,193]. lkb1 is a critical regulator of cell polarity and energy/metabolism control and exerts it vast effects via diverse effectors [138,194,195].",pmc3660063,1,10,5,1,15
2581,pi3k,protein,,,,,,,akt,protein,,,,,,,positive,i,deregulated,,,,,human,['3655'],nan,nan,"there is extensive evidence from the molecular and genomic analysis of human cancers presented above that the pi3k/akt pathway is deregulated in malignant progression [449]. furthermore, the causal involvement of pi3k is supported by gene-knockout mouse models. prototype inhibitors such wortmannin and ly294002 have show evidence of anticancer activity in vitro and in vivo animal models. therefore, the recent development of isoform-selective inhibitors shows considerable promise for cancer treatment [450-452].",pmc2652403,1,10,5,1,15
3404,tsc2,protein,,tsc2,uniprot,p49815,,,irs-1,protein,,irs1,uniprot,p35568,,,positive,i,dependent on,,,,,,['681'],nan,nan,irs-1 mrna and protein expression is dependent on tsc2. (a) microarray analysis of tsc2,pmc2172316,1,10,5,1,15
169,akt,protein,,akt1,uniprot,p31749,,,mtor,protein,,mtor,uniprot,p42345,,,positive,i,regulation,,anch,,,,['2626'],nan,nan,"as the upstream regulator of mtor, akt is typically a suppressor of autophagy.36, 42 however, akt inhibitors failed to stimulate autophagy in rasfonin-treated cells. indeed, inhibitors of pi3k, an upstream kinase of akt, either stimulate or inhibit autophagy.43, 44 recently, the class ia pi3k p110-β subunit, an upstream regulator of akt, was reported to positively regulate autophagy.45 in the present study, we also observed that akt1/2 depletion attenuated the induced autophagy in anch cells. moreover, the overexpression of activated akt stimulated the induced autophagic flux in a time- and akt isoform-specific manner. these findings indicated that akt is unlikely to consistently function as an autopahgy suppressor. therefore, we speculated that akt might regulate autophagic process in a context-dependent manner.",pmc4720880,1,10,5,1,15
2149,myr-akt1,protein,,akt1,uniprot,p31749,,,p16,protein,,cdkn2a,uniprot,p42771,,,positive,i,induction,,bj-t cells,fibroblast,,,['3348'],nan,nan,"we next compared the saβgal levels and the p53, p21 and p16 responses to the expression of myr-akt1 and h-rasv12 at multiple time points (supplementary figure 2). myr-akt1 expression induced a more rapid and complete induction of senescence than h-rasv12 up to 11 days post-retroviral infection (supplementary figure 2a). at early time points following transduction (days 5 and 8), p21 expression increased rapidly in akt-expressing cells (supplementary figure 2b), whereas no increase was observed in ras-expressing cells until day 10 (figure 2a) and day 12 (supplementary figure 2b). despite the incomplete senescence response of the h-rasv12-expressing population (30–40% of cells positive for saβgal activity), we observed robust p16 induction at days 10–12 in these cells; however, we did not detect major p16 increases in the myr-akt-expressing bj-t cells.",pmc3325598,1,10,5,1,15
2327,p38 mapk,protein,mapk,mapk14,uniprot,p45983,cytoplasm,go:0005737,autophagy,process,,,go,go:0006914,cytoplasm,go:0005737,positive,i,regulation,,colon cancer ht29 cells,transformed and non-transformed cells,primary cells,human,['664'],nan,nan,"several studies have shown an evolutionarily conserved role for p38 mapk in the regulation of autophagy [17], [18], [29]. however, the cell type-specific induction of defective autophagic vacuoles by sb202190 and sb203580 seen in colon cancer ht29 cells, which we extended to other transformed and non-transformed cells types including primary cells, is a p38 mapk-independent effect of these compounds. this effect of sb compounds in ht29 cells seems to be biphasic, involving an initial phase which leads to initiation of lc3 conjugation and active autophagic degradation followed by the blockade of autophagic proteolysis, leading to the accumulation of acidic vacuoles, p62 and lc3-ii. using further inhibitors of p38 mapk and a sb-resistant mutant of p38 mapkα, we could show that inhibition of p38 mapk is not sufficient for this effect and that the effect even does not require suppression of p38 mapk activity. since vacuolization is also detected after act-d treatment, the cell type-specific changes in pro-autophagic gene expression reported in colon cancer [19], [30] and other cells [17] in response to sb202190 treatment seem to be dispensable for the formation of acidic autolysosomes. the kinetics of vacuole formation, gene expression and fhre reporter activation suggest that changes in gene expression could be a feed-forward control of already induced vacuoles, or a result of blockade of basal autophagy, leading to accumulation of enlarged autophagolysosomes and cell death. contradictory data exist in the literature about the correlation between p38 activity, foxo3a transcriptional activation and pro-autophagic gene expression [19], [31]. since these studies utilized sb compounds to study the involvement of p38, these effects needs to be re-evaluated.",pmc3154272,1,10,5,1,15
2340,p53,protein,dominant-negative,tp53,uniprot,p04637,nucleus,go:0005634,pi 3-kinase,protein,,pik3ca,uniprot,p42336,cytoplasm,go:0005737,negative,i,inhibition,,rat-1,fibroblast,,human,['503'],nan,nan,"we investigated the effect of dominant-negative p53 expression on apoptosis in response to inhibition of pi 3-kinase by treating cells with the small-molecule inhibitor, pi-103.36 inhibition of pi-3 kinase rapidly induced apoptosis in both wild-type rat-1 cells and cells expressing dominant-negative p53, as indicated by dna fragmentation as early as 1 h after treating with pi-103 (figure 1c). however, quantification by tunel assays indicated that apoptosis was significantly inhibited in both clones expressing the dominant-negative p53 mutant (figure 1d). these results indicate that p53 contributes to but is not essential for apoptosis in response to inhibition of pi 3-kinase. similar results were obtained following treatment with gdc-0941, which is a more specific pi 3-kinase inhibitor that does not affect mtor or related protein kinases37 (see figure 8).",pmc3481126,1,10,5,1,15
2354,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,negative,i,degradation,,bj-t,fibroblast,skin,human,['3356'],nan,nan,"to investigate the mechanism by which p53 accumulates in akt-expressing bj-t cells, p53 stability was assessed by [35s]met/cys pulse-chase analysis. over the 60 min chase period, [35s]met/cys-labelled p53 reduced at a slower rate in myr-akt cells compared to pbabe cells, indicating that myr-akt expression decreased p53 turnover (figure 6a). importantly, a 45% increase in p53 synthesis was observed in the 30 min pulse period in myr-akt-expressing cells compared with control cells (figure 6b), with no change in relative p53 transcript levels detected (supplementary figure 4a). furthermore, rapid lysis of pbabe- or myr-akt-expressing cells plus or minus the proteasome inhibitor mg132 treatment indicated that akt-expressing cells had reduced levels of polyubiquitinated p53 in the steady state (figure 6c). these results indicate that p53 accumulation in akt cells results from both a reduction in mdm2-mediated p53 ubiquitination and degradation, plus enhanced p53 translation.",pmc3325598,1,10,5,1,15
2355,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,i,promotes,,,,,human,['3355'],nan,nan,"taken together, these results indicate that p53 knockdown specifically regulates the induction of senescence markers by activated akt and, unlike the case of h-rasv12 (serrano et al., 1997), is sufficient to rescue cell proliferation. these results are intriguing given that previous reports demonstrate that akt promotes the activity of the e3 ubiquitin ligase mdm2 (ogawara et al., 2002), the important negative regulator of p53 (haupt et al., 1997; kubbutat et al., 1997). post-translational modifications, protein–protein interactions and/or alterations to cellular localisation of either p53 or mdm2 can block the p53:mdm2 interaction resulting in p53 stabilisation (meek and knippschild, 2003).",pmc3325598,1,10,5,1,15
2373,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,positive,i,stabilization,,hct116,colon cancer,colon,human,['3043'],nan,nan,"in order to explore the mechanism of etoposide-induced increase in mtor protein level, hct116 p53+/+ and p53−/− cells were either treated with cycloheximide, an inhibitor of protein synthesis, or the proteasome inhibitor, mg-132 (figure 2c). incubation of cells with cycloheximide alone resulted in inhibition of mtor protein suggesting a requirement for ongoing protein synthesis to maintain basal mtor levels. however, the etoposide-mediated increase in mtor protein accumulation was still observed in both p53+/+ and p53−/− hct116 cells in the presence of cycloheximide, indicating that etoposide-mediated increase in mtor was unlikely due to increased protein synthesis. we next investigated the effect of mg-132 on the level of mtor in hct116 cells. treatment of cells with mg-132 for 4 hrs led to an accumulation of mtor protein similar to that observed for etoposide treatment (figure 2c), either in the absence or presence of cycloheximide, further suggesting that etoposide-mediated upregulation of mtor was not dependent on protein synthesis, but rather due to stabilization of mtor.",pmc4381605,1,10,5,1,15
2385,p53,protein,serine/threonine phosphatase,tp53,uniprot,p04637,nucleus,go:0005634,mdm2,protein,wip1 substrate,mdm2,uniprot,q00987,nucleus,go:0005634,positive,i,dephosphorylation,s395,,epithelial,,human,['1679'],nan,nan,"not only is p53 regulated by multiple protein serine/threonine phosphatases directly, but it is also regulated indirectly through the regulation of mdm2. mdm2 has been predicted to be a wip1 substrate [145]. indeed, wip1, but not pp2a, dephosphorylated mdm2 at s395, which is an atm phosphorylation site [79,146]. wip1 dephosphorylation of s395 increased the stability of mdm2 and increased the mdm2-p53 interaction. wip1 inhibited mdm2 auto-ubiquitination thereby stabilizing the protein [146].",pmc2954851,1,10,5,1,15
2575,pi3k,protein,kinase,pik3ca,uniprot,p42336,cell membrane,go:0005886,mtor,protein,kinase,mtor,uniprot,p42345,cytoplasm,go:0005737,positive,i,phosphorylation,ser-2448,,cancer,,human,['939'],nan,nan,"the pi3k, akt, erk, and mtor prosurvival mediators are important therapeutic targets, as they are constitutively activated in many cancers and contribute to cancer progression by promoting cellular proliferation and inhibiting cell death signalling pathways (falasca, 2010). phosphoinositide 3-kinase (pi3k) is activated at the cell membrane by tyrosine kinase growth factor receptors, such as members of the epidermal growth factor receptor family (egfr and her-2), and by the insulin-like growth factor-1 receptor (igfr), as well as its downstream signalling substrate irs-1 (insulin receptor substrate-1; schlessinger, 2000). phosphoinositide 3-kinase promotes cancer cell survival by activation of downstream mediators akt and ras, the latter leading to erk activation (mccubrey et al, 2007). akt exerts its survival role via a diverse array of substrates, which control key cellular processes, including apoptosis, cell cycle progression, transcription, and translation (chang et al, 2003). a major downstream substrate of akt is the serine/threonine kinase mtor. akt can directly phosphorylate mtor at ser-2448 and activate it, as well as cause indirect activation of mtor by phosphorylating and inactivating tsc2 (tuberous sclerosis complex 2, also called tuberin). the raptor–mtor complex signals to its downstream effectors s6 kinase/ribosomal protein s6 (p70s6k) and the eif4e-binding protein (p4e-bp1) to control transcription and translation, which selectively regulates multiple proteins that control cell cycle and apoptosis (gibbons et al, 2009). additionally, akt can directly regulate apoptosis by phosphorylating and inactivating proapoptotic proteins such as bad and caspase-9 (datta et al, 1997; cardone et al, 1998; mabuchi et al, 2002). extracellular signal-regulated kinase (erk) exerts its antiapoptotic effects by phosphorylating and inactivating bad (mabuchi et al, 2002). as with most intracellular signalling cascades, cross-talk and negative and positive feedback loops complicate final signalling outcomes.",pmc3039802,1,10,5,1,15
2027,mtor,protein,,,uniprot,p42345,cytoplasm,go:0005737,ampk,protein,,prkaa1/prkaa2,uniprot,o43741/o43741,cytoplasm,go:0005737,negative,i,activation,,a549/h1299,epithelial,lung,human,['1486'],nan,nan,"mtor activity is suppressed under conditions of energy deprivation in which depleted atp levels trigger ampk activation.21 we further investigated whether ampk is involved in mtor inhibition induced by twist1 suppression. as shown in figure 6b, treatment with twist1 sirna stimulated phosphorylation of ampk and the ampk substrate, acetyl-coa carboxylase, in a549 and h1299 cells. moreover, suppression of twist1 led to a marked increase in the cellular adp/atp ratio, indicating a decrease in the atp content in both cell types (figure 6a). to establish the involvement of ampk in twist1 sirna-induced mtor inhibition, we transfected cells displaying twist1 downregulation with ampkα1/2 sirna. downregulation of ampk led to recovery of mtor activity inhibited by twist1 sirna (figure 6c). our results collectively suggest that silencing of twist1 expression is associated with atp depletion, leading to ampk-activated mtor inhibition.",pmc3388235,1,10,5,1,15
446,braf,protein,,braf,uniprot,p15056,cytoplasm,go:0005737,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,positive,i,influence,,,melanoma,skin,human,['887'],nan,nan,"overall, the alterations in major components of the mapk, such as braf and nras mutations, and mtor pathways, pten loss and akt overexpression, seem to have substantial influence in melanoma progression, being both pathways linked to survival and chemoresistence in melanoma [3,171,172].",pmc3291999,1,10,5,1,15
2010,mtor,protein,,mtor,uniprot,p42345,,,chk1,protein,,chek1,uniprot,o14757,,,negative,i,inhibition,translation,"hek293, hct116",,,human,['3048'],nan,nan,"since mtor inhibition in hek293 cells significantly reduced the total chk1 level following etoposide treatment (figure 3), we explored how mtor regulates chk1 protein in these cells. the reduction in chk1 level caused by mtor inhibition could be due to faster degradation of chk1 or inhibition of its production at transcriptional or translational level. therefore, we first observed the half-life of chk1 using cycloheximide. in agreement with past reports [34-36] the turnover of chk1 protein was significantly increased by etoposide-induced dna damage in both hek293 and hct116 cells (figure 5a). mtor inhibition with pp242 following dna damage did not further increase chk1 turnover, therefore it is unlikely that the decrease in chk1 caused by mtor inhibition is due to an increase in chk1 degradation. unexpectedly, pp242 in fact reduced chk1 turnover following dna damage. zhang [34] demonstrated that dna damage induced phosphorylation of chk1 at ser345 targets it for ubiquitin-mediated proteasomal degradation. since we observed that pp242 inhibited chk1 phosphorylation at ser345, this could account for why chk1 degradation is prevented. nevertheless, total chk1 is still reduced by mtor inhibition following etoposide-induced dna damage. therefore, these results indicate that mtor inhibition causes chk1 reduction by inhibiting its production. next we measured chk1 mrna levels using rt-pcr and found that they were not changed by etoposide-induced dna damage, nor by mtor inhibition with pp242 (figure 5b). thereby showing that mtor regulation of chk1 protein production is not mediated through transcription. however, in the presence of cycloheximide chk1 level is efficiently suppressed before and after dna damage, more importantly pp242 did not cause a further reduction in chk1 (figure 5c) implying that chk1 reduction caused by mtor inhibition is mediated by preventing its synthesis at translation level. these results collectively suggest that following etoposide-induced dna damage mtor regulates chk1 production through protein synthesis. figure 5c further supports our concept that mtor is required for chk1 phosphorylation and activation independently from its regulation of total chk1 protein. in the presence of cycloheximide, total chk1 is suppressed but not further reduced by pp242. in the presence of cycloheximide, all three etoposide-induced chk1 phosphorylations are reduced but pp242 causes additional reduction.",pmc4381605,1,10,5,1,15
2717,pras40,protein,,akt1s1,uniprot,q96b36,,,p53,protein,,tp53,uniprot,p04637,,,negative,i,inhibiting,,u2os,osteosarcoma,bone,,['2287'],nan,nan,"to test if the observed pras40 kd-induced p53 and p21 upregulation (figs. 5a,d,e) corresponds to increased p53 transcriptional activity we used a p53 reporter plasmid in which luciferase transcription is driven by the consensus p53-binding promoter sequence. pras40 kd significantly increases p53 transcriptional activity compared to the ns control. importantly, this effect is abolished by co-kd of either p53 or rpl11 (fig. 5i). finally, we tested whether pras40 kd-induced p53 upregulation has any effect on cell survival or growth. in order to suppress tumorigenesis, p53 transcriptional targets are known to induce cell death, temporary cell cycle arrest, or a permanent loss of replicative potential known as senescence. while we are not able to detect significant induction of cell death in u2os cells, pras40 depletion significantly increases senescence-associated β-galactosidase activity compared to ns control cells. importantly, this effect is abrogated by co-kd of p53 (fig. 5j). taken together, our results suggest that pras40 negatively regulates p53 stability and activity by inhibiting the rpl11-hdm2 pathway in a manner dependent upon pras40-rpl11 association, thereby helping to suppress p53-mediated induction of senescence in unstressed cells.",pmc4216640,1,10,5,1,15
2897,ras,protein,,,,,,,erk,protein,,,,,,,positive,i,phosphorylation,,,,,human,['2890'],nan,nan,"extracellular signal-regulated kinase (erk) is another critical downstream kinase in growth factor signaling and plays an essential role in cancer cell proliferation (robinson and cobb, 1997; sebolt-leopold, 2000). the ras–raf–mek–erk pathway is a well-characterized signaling pathway and is commonly activated in multiple human cancers. studies have shown that ras and raf are frequently mutated in various human cancer types and responsible for cancer progression (adjei, 2001; davies et al., 2002). therefore, this signaling pathway has been considered a drug target for cancer therapy, and a variety of inhibitors have been developed, including mek or raf inhibitors (davies et al., 2007; bollag et al., 2010; hatzivassiliou et al., 2010; maurer et al., 2011).",pmc3355968,1,10,5,1,15
916,dominant-negative p53,protein,,,uniprot,p04637,,,pi 3-kinase,protein,,pik3ca,uniprot,,,,negative,i,inhibition,,,,,,['513'],nan,nan,"expression of dominant-negative p53 inhibited but did not prevent apoptosis resulting from inhibition of pi 3-kinase. this is consistent with previous reports that p53 contributes to apoptosis induced by growth factor deprivation42, 43, 44 and indicates that p53 is one of the effectors contributing to cell death when pi 3-kinase signaling is blocked. our current results on the effects of p53 on transcriptional changes in response to pi 3-kinase inhibition were consistent with this partial effect on apoptosis. the expression of about half of the genes induced in response to inhibition of pi 3-kinase was reduced in cells expressing dominant-negative p53, although the effect of dominant-negative p53 on most of these genes was a partial rather than complete block to their induction. consistent with the partial effect of p53 on gene induction, the genes induced by inhibition of pi 3-kinase in rat-1 cells were also targeted by foxo, mitf and usf1 transcription factors, as previously reported in human t98g cells.16, 18",pmc3481126,1,10,5,1,15
2892,ras,protein,,,fplx,ras,,,raf,protein,,,fplx,raf,,,positive,i,activation,,,,,human,['1981'],nan,nan,"in this review, we have discussed the various types of mutations which occur in the ras/raf/mek/erk and ras/pi3k/akt/mtor pathways and how they can lead to cancer as well as other diseases. we discussed certain classes of genes important in cancer such as oncogenes, tumor suppressor, caretaker and gatekeeper genes. it is obvious that there are many genes which can fit into more than one category. we have introduced the concepts of driver, gatekeeper, passenger, lineage-specific and synthetic lethal mutations so that the reader will have a concept of how these different classes of mutations can contribute to cancer and have been used to identify key interacting genes. we have discussed the concepts of oncogene-addiction, oncogene-bypass and kinase-switching and how they can be important in identifying the key components involved in the growth of the cancer cell and how they may change during treatment with targeted therapy. mutations at many of the upstream receptor genes or ras can result in abnormal raf/mek/erk and pi3k/pten/akt/mtor pathway activation. hence targeting these cascade components with small-molecule inhibitors may inhibit cell growth. the usefulness of these inhibitors may depend on the mechanism of transformation of the particular cancer. if the tumor exhibits a dependency on the ras/raf/mek/erk pathway, then it may be sensitive to raf and mek inhibitors. in contrast, tumors that do not display enhanced expression of the ras/raf/mek/erk pathway may not be sensitive to either raf or mek inhibitors but if the ras/pi3k/akt/mtor pathway is activated, it may be sensitive to specific inhibitors that target this pathway.",pmc3660063,1,10,5,1,15
385,b-raf v599e mutants,protein,mutant,braf,uniprot,p15056,plasma membrane,go:0005886,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,positive,i,inhibition,,melanoma,melanoma,skin,human,['2450'],nan,nan,"our interest is in combining targeted agents for these pathways in an effort to determine if such treatments will be effective in the treatment of melanoma. we hypothesized that the combination of multiple targeted therapeutic agents would result in enhanced inhibition of melanoma cell proliferation compared to either drug alone, because of synergy between effects on two pathways. here we show that serum-stimulated melanoma cell proliferation is inhibited by either rapamycin or bay43-9006, with b-raf v599e mutants showing an increased sensitivity to each drug at 10 nm compared to melanoma cells with wild-type b-raf. each of these drugs inhibited the serum-stimulated phosphorylation of known raf and mtor substrates. what was unexpected was that each of the drugs inhibited phosphorylation in both the raf and mtor pathways, suggesting there was interdependence or cross-talk between these pathways in melanoma cells. furthermore, the combination of rapamycin with bay43-9006 was synergistic compared to either drug alone at inhibiting proliferation of wild-type b-raf and v599e mutant b-raf melanoma cell lines.",pmc1289294,1,10,5,1,15
314,arf,protein,tumor suppressor,cdkn2a,uniprot,p42771,nucleus,go:0005634,p53mut,protein,mutant p53,tp53,uniprot,p04637,nucleus,go:0005634,positive,i,stabilization,,,tumor,prostate,human,['402'],nan,nan,"an interesting aspect of this study is that although arf is a well characterized tumor suppressor [93] the observation that arf contributes to the resistance against ir through stabilization of p53mut and inhibition of p73, suggests that in some circumstances arf behaves as an oncogene. interestingly other reports have suggested arf has oncogenic activity than can affect tumor growth in a tissue specific manner [94, 95]. independent of p53, human prostate tumors with pten loss show increased arf expression which correlates with the increased aggressiveness of disease [95]. furthermore, arf has been shown to protect tumor cells from metabolic stress by promoting the induction of autophagy [94]. these reports argue that in specific tissues arf can exert tumor promoting activity that is distinct from regulation of p53. however, our data and recent reports from others argue that an additional aspect of an oncogenic role for arf is the maintenance of p53mut stability. pml knockout mice on a p53mut background displayed stabilization of p53mut with expression of arf, suggesting that loss of pml promotes oncogenic activation of arf which in turn stabilizes p53mut through inhibition of mdm2 [28]. further evidence for a role in arf mediated stabilization of p53mut came from a study that demonstrated tgf-β1 induced destabilization of p53mut by inhibiting e2f-1 mediated transcription of arf [96]. interestingly, akt has been demonstrated to increase arf transcription by relieving bmi1 repression of arf transcription [97] and therefore provides a potent mechanism to stabilize p53mut via the elevated transcription and nucleoplasmic localization of arf.",pmc4171619,1,10,5,1,15
1003,egfr,protein,,,unknown,unknown,,,pi3k,protein,,,unknown,unknown,,,positive,i,inhibited,,unknown,unknown,unknown,unknown,['3649'],nan,nan,"cells transformed by oncogenic ras, display a radioresistant phenotype in response to ionizing radiation (ir). the pi3k inhibitor ly294002 radiosensitized cells bearing mutant ras, but the survival of cells with wild-type ras was not affected [436]. in another study, the mechanisms by which ras mediates radioresistance in epithelial cells were assessed [437]. the importance of three major survival pathways that can be activated by ras (pi3k/akt, nf-κb, and raf/mek/erk) were investigated as necessary or sufficient for ras-mediated radioresistance in matched pairs of epithelial cells expressing oncogenic ras or empty vector [437]. inhibiting pi3k with ly294002 sensitized cells expressing oncogenic ras to ir, indicating that pi3k is necessary for ras-mediated radioresistance [437]. another study suggested that a combination of the pi3k inhibitor ly294002 and conventional chemotherapy (paclitaxel) may provide an effective approach to inhibiting tumor growth and ascites production in ovarian cancer with acceptable side effects [438]. ly294002 demonstrated a growth-inhibitory and apoptosis-inducing effect in colon cancer cell lines, with decreased expression of phosphorylated akt [439]. in experiments using mouse xenografts, it was found that ly294002 administration in vivo also resulted in suppression of tumor growth and induction of apoptosis [439]. resistance to conventional adjuvant therapies (chemotherapy and radiation) has been well documented in malignant gliomas. in vitro, an actual antagonistic effect between sequential administration of radiation and 1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) chemotherapy in primary human glioblastoma cell lines was observed, which was abrogated upon inhibition of egfr with the a tyrosine kinase inhibitor [440]. it was found that bcnu inhibited radiation-induced apoptosis through egfr-mediated activation of pi3k/akt via ras [440].",pmc2652403,1,10,5,1,15
2561,pi 3-kinase,protein,,,uniprot,p42336,,,akt,protein,,akt1,uniprot,p31749,,,positive,i,signaling,,,,,human,['499'],nan,nan,"the phosphatidylinositol (pi) 3-kinase/akt signaling pathway has a central role in the growth and survival of both normal and malignant cells.1, 2 signaling by pi 3-kinase downstream of growth factor receptors is required to suppress apoptosis of most mammalian cell types, as well as acting to stimulate cell proliferation. oncogenic mutations affecting the pi 3-kinase/akt pathway are among the most common abnormalities found in human tumors, and inhibitors of pi 3-kinase are currently being evaluated as cancer chemotherapeutic agents in clinical trials.1, 2",pmc3481126,1,10,5,1,15
2646,pik3ca,protein,,pik3ca,uniprot,p42336,cytoplasm,go:0005737,tor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,positive,i,activation,,chicken embryo fibroblasts,fibroblast,chorioallantoic membrane,chicken,['3640'],nan,nan,"the oncogenic potential of three of the most commonly observed pik3ca mutations (e542k, e545k, h1047r) was investigated in chicken embryo fibroblasts [401]. all three mutants induced oncogenic transformation with high efficiency [401]. the mutant-transformed cells displayed constitutive phosphorylation of akt, of p70(s6k), and of the 4e-bp1 [401]. rapamycin strongly suppressed cellular transformation induced by the pi3k mutants, suggesting that tor and its downstream targets are essential components of the transformation process [401]. it was also shown that three prevalent mutants of p110α are oncogenic in vivo [402]. the mutants induced tumors in the chorioallantoic membrane of the chicken embryo and caused hemangiosarcomas in the animal [402]. these tumors were marked by increased angiogenesis and an activation of the akt pathway [402]. the tor inhibitor rad001 blocked tumor growth induced by the h1047r p110α mutant [402]. in a subsequent study, all of eight pik3ca mutations examined were shown increased p110α lipid kinase activity compared with the wild-type enzyme [403]. all the mutants strongly activated akt and p70(s6k) and also induced morphologic changes, loss of contact inhibition, and anchorage-independent growth of nih3t3 cells [403]. the hotspot mutations e542k, e545k, and h1047r, all had high enzymatic and transforming activities [403]. these results showed that almost all the colon cancer-associated pik3ca mutations are functionally active so that they are likely to be involved in carcinogenesis [403]. in a recent report, a panel of rare pik3ca mutants was evalulated in chicken fibroblast tansformation assays, which also revealed their oncogenic potential and mechanism of activation [404].",pmc2652403,1,10,5,1,15
170,akt,protein,,akt1,uniprot,p31749,,,mtorc1,complex,,,,,,,positive,i,relief,,,,,,['3366'],nan,nan,"the dependence of akt-induced senescence on mtorc1 activity has direct implications for the use of mtorc1 inhibitors as anticancer agents. inhibitors such as rad001 and cci-779 have delivered limited therapeutic benefit as single agents (brachmann et al., 2009). this lack of effect has been attributed, at least in part, to the inactivation of mtorc1-dependent negative feedback of pi3k/akt signalling (o'reilly et al., 2006) and/or the activity of the ras pathway (carracedo et al., 2008). our data provide another level of potential concern where mtorc1 inhibition may relieve the senescence ‘brake' in p53 wild-type cells and promote pi3k-dependent transformation. targeted therapies are now being designed and tested that will alleviate the pro-tumourigenic effects of mtorc1 inhibition. these include mtor active site inhibitors that will target both mtorc2-dependent akt activation and mtorc1-dependent growth (feldman et al., 2009; dowling et al., 2010; hsieh et al., 2010), dual pi3k/mtor inhibitors (bhatt et al., 2010) or the use of the mdm2 antagonist nutlin-3a in combination with mtor inhibition (alimonti et al., 2010b).",pmc3325598,1,10,5,1,15
1654,irs,protein,adaptor protein,irs,hgnc,6119,,,egfrs,protein,,egfr,,,,,positive,i,signaling,,,,,,['2694'],nan,nan,"the model analyzed interactions that involve five key network nodes, the adaptor proteins gab1 and irs, pi3k/pip3, soluble tyrosine kinase src and protein tyrosine phosphatase shp2, which are all localized upstream of mek/erk. together, these nodes contribute to the amplification of erk signaling in the context of multiple interactions, which involve insulin and egfrs, grb2–sos, rasgap, as well as positive and negative feedback controls from downstream targets of insulin and egf. the model explains how the network structures, which involve (i) gab1-mediated insulin and egf coincidence detection, (ii) coherent feed-forward loop from egfr to raf via src, and (iii) multiple positive (pi3k–pip3–gab1–pi3k) and negative (erk–gab1, erk–sos, mtor–irs) feedback loops contribute to the control of insulin plus egf signaling (a network motif where an initial input signal (a) induces an intermediate input signal (b), and both the initial and intermediate inputs are needed to generate the final output (c), is referred as a coherent feed-forward loop (mangan et al, 2003)). the simplified scheme shown in figure 6 illustrates how insulin enhances egf-induced mitogenesis through two partially redundant and compensating signaling branches via irs and gab1. the goal of our computational model is to predict and explain a large number of diverse patterns of signaling dynamics obtained from our own experiments and literature data. we applied in silico perturbations to our model and, wherever possible, verified the predicted temporal dynamics in vivo. our strategy is similar to the so-called pattern-oriented modeling, in which a large number of quantitative and also qualitative patterns help us exclude models that are too simple in structure or too uncertain experimentally (grimm et al, 2005).",pmc2683723,1,10,5,1,15
1660,irs-1,protein,,irs1,uniprot,p35568,,,pkb,protein,,akt1,uniprot,p31749,,,positive,i,phosphorylation,ser473,mefs,fibroblast,,mouse,['697'],nan,nan,"−/− mefs stimulated by insulin for 10 min after treatment with 20 nm rapamycin for 1 h. first panel, irs-1; second panel, irs-2; third panel, ser473-phosphorylated pkb; bottom panel, total pkb. (f) rescue of pkb activation in tsc2",pmc2172316,1,10,5,1,15
2604,pi3k,protein,,pik3ca,uniprot,p42336,,,hif-1,protein,transcription factor,,uniprot,q16665,nucleus,go:0005634,positive,i,activation,,,cancer,,human,['3607'],nan,nan,"pi3k signaling plays a key role in tumor angiogenesis, the development of new blood vessels. hypoxia develops in the majority of solid tumors due to the inability of the existing vascular system to supply the growing tumor mass with adequate amounts of oxygen [251]. a large body of clinical evidence suggests that intratumoral hypoxia correlates with the elevated aggressive behavior of cancer cells and their resistance to therapy, leading to poor patient prognoses [251]. hypoxia-inducible factor 1 (hif-1) is a transcriptional activator that functions as a master regulator of o2 homeostasis [252]. hif-1 target genes encode proteins that increase o2 delivery and mediate adaptive responses to o2 deprivation [252]. several hif-1 targets are known, including the gene encoding vascular endothelial growth factor (vegf). hif-1 activity is regulated by the cellular o2 concentration and by the major growth factor-stimulated signal transduction pathways [252]. in human cancer cells, both intratumoral hypoxia and genetic alterations affecting signal transduction pathways lead to increased hif-1 activity, which promotes angiogenesis, metabolic adaptation, and other critical aspects of tumor progression [252, 253]. hif-1 is a transcriptional activator composed of hif-1α and hif-1β subunits [253, 254]. under hypoxic conditions, hif-1α expression increases as a result of decreased ubiquitination and degradation [254]. the tumor suppressors vhl (von hippel-lindau protein) and p53 target hif-1α for ubiquitination such that their inactivation in tumor cells increases the half-life of hif-1α [254]. increased pi3k and akt or decreased pten activity in cancer cells were also shown to increase hif-1α [255]. a further study observed that hypoxic induction of hif-1α protein was decreased by serum deprivation in carcinoma cells under low oxygen tension [256]. over-expression of dominant-active akt1 restored hif-1α expression, whereas inhibition of pi3k activity reduced hypoxic hif-1α protein levels [256]. an immunohistochemical analysis of human breast cancers revealed that lack of akt1 phosphorylation correlates with low hif-1α levels [256]. the angiogenic switch in ras-transformed cells is promoted by the tumor microenvironment through the induction of the angiogenic mitogen, vegf. it was shown that hypoxia modulates vegf induction in ras-transformed cells through the activation of a stress inducible pi3k/akt pathway and the hif-1 transcriptional response element [257]. hypoxia was reported to activate a growth factor receptor (pdgfr)/pi3k/akt cascade that leads to gsk-3 inactivation, and thus impact on cell survival, proliferation, and metabolism [258]. it was also reported that under hypoxic conditions, rat pheochromocytoma pc12 cells are resistant to apoptosis induced by serum withdrawal and chemotherapy treatment. the hypoxia-dependent protection from apoptosis correlated with activation of the pi3k/akt pathway [259]. in another study, insulin and epidermal growth factor or an inactivating mutation in the tumor suppressor pten specifically increased the protein levels of hif-1α, but not of hif-1β in human cancer cell lines [260]. this specific elevation of hif-1α protein expression required pi3k signaling [260]. another study examined the involvement of foxo4 (also known as afx), a member of the forkhead transcription factor superfamily that is negatively regulated by the pi3k/akt pathway, in the regulation of hif-1α protein expression [261]. nuclear expression of foxo4 resulted in the suppression of various responses to hypoxia, including decreased vegf [261]. interestingly, foxo4 down-regulated the hif-1α protein levels, consistent with the lack of hypoxia responsiveness [261]. in another study, the linkage between mtor and hif-1 in pc-3 prostate cancer cells treated during hypoxia was further explored [262]. pretreatment of pc-3 cells with the mtor inhibitor, rapamycin, inhibited both the accumulation of hif-1α and hif-1-dependent transcription induced by hypoxia [262]. further work pinpointed the oxygen-dependent degradation domain as a critical target for the rapamycin-sensitive, mtor-dependent signaling pathway leading to hif-1α stabilization by hypoxia-inducing agents [262]. these studies position mtor as an upstream activator of hif-1 function in cancer cells and suggest that the anti-tumor activity of rapamycin is mediated, in part, through the inhibition of cellular responses to hypoxic stress [262].",pmc2652403,1,10,5,1,15
1737,lkb1,protein,,stk11,uniprot,q15831,cytoplasm,go:0005737,mtorc1,complex,,,,,cytoplasm,go:0005737,negative,i,inhibiting,,,,,human,['2010'],nan,nan,"lkb1 is an important tumor suppressor and gatekeeper mutations of lkb1 cause the rare peutz-jeghers syndrome (pjs) which is a cancer-prone syndrome [173]. lkb1 is a critical regulator of cell polarity and energy/metabolism control and exerts it vast effects via diverse effectors [174,175]. ampk is considered a metabolic gatekeeper important in many diseases including diabetes, cancer and neurologic disorders. inhibiting mtorc1 activity by drugs such as metformin and other drugs (including rapamycin) may not only aid in the treatment of diabetics, but also improve cancer therapies and increase longevity [176-179].",pmc4102778,1,10,5,1,15
245,ampk,protein,,,,,,,mtorc1,protein,,,,,,,negative,i,suppress,,,,,,['1952'],nan,nan,"ampk is considered a metabolic gatekeeper important in many diseases including diabetes, cancer and neurologic disorders [196-203]. ampk is activated by the diabetes drug metformin [193]. hence metformin will indirectly suppress mtorc1 activity. chronic overfeeding increases mtorc1 activity which in turn promotes adiposity and decreases lifespan and is also believe to enhance cancer growth [204,205]. inhibiting mtorc1 activity by drugs such as metformin and other drugs (including rapamycin) may not only aid in the treatment of diabetics, but also improve cancer therapies and increase longevity [206-216].",pmc3660063,1,10,5,1,15
1848,mek1,protein,,mek1,uniprot,q02750,cytoplasm,go:0005737,raf1,protein,,raf1,uniprot,p04049,cytoplasm,go:0005737,positive,i,phosphorylation,s218 and s222,,,,human,['2934'],nan,nan,"expression vectors for hemagglutinin-tagged wild-type mek1 (wtmek) and camek, with a conversion of s218 and s222 raf1-dependent regulatory phosphorylation sites to aspartic residues, were provided by dr j. pouysségur (nice, france). the ha-wtmek and ha-camek constructs were subcloned into the retroviral expression vector plxin (clontech, mountain view, ca, usa), as previously described.23, 24 the prl-sv40 renilla luciferase reporter vector was from promega (nepean, on, canada). expression vectors encoding for human δntcf4, wt lrp6, lrp6-5a and krasg12v were all provided by addgene (cambridge, ma, usa). the tcf reporter constructs topflash and its negative control fopflash as well as the c-myc promoter reporter (4 × tbe2) and its control (4 × tbe2-mutated) were also purchased from addgene.",pmc4687460,1,10,5,1,15
1971,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,irs-1,protein,,irs1,uniprot,p35568,cytoplasm,go:0005737,negative,i,hyperactivation,,,,,human,['684'],nan,nan,"irs-1 protein levels have previously been shown to be rapamycin sensitive (haruta et al., 2000). because mtor/s6k signaling is hyperactivated in tsc2-deficient cells (jaeschke et al., 2002), we sought to examine the effect of rapamycin on irs-1 mrna abundance. rapamycin treatment of tsc2",pmc2172316,1,10,5,1,15
3406,tsc2,protein,,tsc2,uniprot,p49815,,,mtor,protein,,mtor,uniprot,,,,negative,i,phosphorylation,ser664,,,,,['3070'],nan,nan,"tsc1 and tsc2 are mutated in tuberous sclerosis complex (tsc) patients. in response to low energy levels, tsc2 becomes phosphorylated by ampk, resulting in increased stability of the tsc1/2 complex. the stabilised tsc1/2 complex inhibits mtor and protects cells from energy deprivation-induced apoptosis (see recent reviews by (inoki et al, 2005b; kwiatkowski and manning, 2005)). tsc2 is also phosphorylated by akt leading to its inactivation and consequently to increased mtor activity. furthermore, s6k phosphorylation is elevated in tsc−/− cells and is rapidly abrogated by rapamycin treatment. activation of the extracellular signal-regulated kinase (erk) by the ras signaling pathway also leads to tsc1/2 inactivation through phosphorylation of tsc2 on ser664 (ma et al, 2005). taken together, the tsc1/2 complex functions as a key player in the regulation of the mtor pathway by receiving inputs from pi3k/pten/akt and ras signalling pathways, energy levels, and amino acids to regulate translation initiation and affect cell growth and proliferation.",pmc2361102,1,10,5,1,15
1820,mek,protein,,,uniprot,,,,erk,protein,,,uniprot,,,,positive,i,activation,,,,,human,['3232'],nan,nan,"the raf-mek-erk pathway is commonly activated in human cancers, largely attributable to the extracellular signal-regulated kinases (erks) being a common downstream target of growth factor receptors, ras, and raf. elevation of these up-stream signals occurs frequently in a variety of malignancies and erk kinases play critical roles in promoting cell proliferation. therefore, inhibition of mek-mediated erk activation is very appealing in cancer therapy. consequently, numerous mek inhibitors have been developed over the years. however, clinical trials have yet to produce overwhelming support for using mek inhibitors in cancer therapy. although complex reasons may have contributed to this outcome, an alternative possibility is that the mek-erk pathway may not solely provide proliferation signals to malignancies, the central scientific rationale in developing mek inhibitors for cancer therapy. recent developments may support this alternative possibility. accumulating evidence now demonstrated that the mek-erk pathway contributes to the proper execution of cellular dna damage response (ddr), a major pathway of tumor suppression. during ddr, the mek-erk pathway is commonly activated, which facilitates the proper activation of ddr checkpoints to prevent cell division. inhibition of mek-mediated erk activation, therefore, compromises checkpoint activation. as a result, cells may continue to proliferate in the presence of dna lesions, leading to the accumulation of mutations and thereby promoting tumorigenesis. alternatively, reduction in checkpoint activation may prevent efficient repair of dna damages, which may cause apoptosis or cell catastrophe, thereby enhancing chemotherapy’s efficacy. this review summarizes our current understanding of the participation of the erk kinases in ddr.",pmc3330700,1,10,3,1,13
448,braf,protein,,braf,uniprot,p15056,,,mek1,protein,,map2k1,uniprot,q02750,,,positive,i,signaling relay,nucleus,,intestinal epithelial,intestine,human,['2905'],nan,nan,"braf relays its signals via the mapk kinases mek1 and mek2, which in turn activate erk1 and erk2. activated erk1/2 then translocate into the nucleus where they phosphorylate and activate many nuclear transcription factors enhancing gene transcription.17 studies on normal intestinal epithelial cells (iecs) in culture have demonstrated a close correlation between erk1/2 activation and g1/s phase transition, whereas pharmacological or molecular inhibition of erk1/2 abrogated cell proliferation.18, 19, 20 notably, we previously localized activated forms of erk1/2 in the nucleus of undifferentiated proliferative epithelial cells in the human intestine.18 the involvement of mek/erk signaling in intestinal tumorigenesis is supported by a number of observations.20 first, mek1/2 are phosphorylated and activated in 30–40% of adenomas and 76% of colorectal tumors.21, 22 second, expression of a constitutively active mutant of mek1 or mek2 in rodent normal iecs is sufficient to induce growth in soft agar, epithelial to mesenchymal transition (emt) and formation of invasive metastatic tumors in nude mice.23, 24, 25, 26 third, synthetic mek inhibitors inhibit intestinal polyp growth in apcmin/+ mice22 and attenuate proliferation of human crc cells in culture and in mouse xenografts.27 taken together, these data strongly suggest that mek/erk signaling may contribute to colorectal carcinogenesis.20 however, the exact molecular mechanisms by which mek/erk signaling achieves such functions in the colon and rectum remain unclear.",pmc4687460,1,10,3,1,13
1013,egfr,protein,transmembrane receptor tyrosine kinase,egfr,uniprot,p00533,cell membrane,go:0005886,egfr,protein,transmembrane receptor tyrosine kinase,egfr,uniprot,p00533,cell membrane,go:0005886,positive,i,phosphorylation,y845,a431,epidermoid carcinoma,skin,human,['1386'],nan,nan,"the src gene product (src) and the epidermal growth factor receptor (egfr) are prototypes of oncogene products and function primarily as a cytoplasmic non-receptor tyrosine kinase and a transmembrane receptor tyrosine kinase, respectively. the identification of src and egfr, and the subsequent extensive investigations of these proteins have long provided cutting edge research in cancer and other molecular and cellular biological studies. in 1995, we reported that the human epidermoid carcinoma cells, a431, contain a small fraction of src and egfr in which these two kinase were in physical association with each other, and that src phosphorylates egfr on tyrosine 845 (y845) in the src-egfr complex. y845 of egfr is located in the activation segment of the kinase domain, where many protein kinases contain kinase-activating autophosphorylation sites (e.g., camp-dependent protein kinase, src family kinases, transmembrane receptor type tyrosine kinases) or trans-phosphorylation sites (e.g., cyclin-dependent protein kinase, mitogen-activated protein kinase, akt protein kinase). a number of studies have demonstrated that y845 phosphorylation serves an important role in cancer as well as normal cells. here we compile the experimental facts involving src phosphorylation of egfr on y845, by which cell proliferation, cell cycle control, mitochondrial regulation of cell metabolism, gamete activation and other cellular functions are regulated. we also discuss the physiological relevance, as well as structural insights of the y845 phosphorylation.",pmc3709701,1,10,3,1,13
444,braf,protein,mutated,braf,uniprot,p15056,cytoplasm,go:0005737,mek,protein,active,map2k1,uniprot,q02750,cytoplasm,go:0005737,positive,d,activation,,wm266-4,melanoma,,human,['2078'],nan,nan,"in melanoma cells expressing the oncogenic mutated braf mek is constitutively active, but treatment with the mek inhibitor selumetinib suppresses this activity and this can be detected in a loss of phosphorylation of erk (fig.1a). at selumetinib concentrations that lead to efficient loss of erk phosphorylation in wm266-4 cells, their proliferation is almost completely suppressed (fig.1b). following this confirmation of previous findings in melanoma cells (5, 8), we analysed the impact of mek inhibition on cell growth in a 3d environment and monitored wm266-4 spheres embedded in fibrillar collagen. selumetinib efficiently suppressed wm266-4 cell growth, and at a concentration of 1μm also induced cell death over a period of 72 hours. however, not all cells died and surprisingly we found surviving cells invading the collagen gel as individual cells in a significant distance to the original sphere (fig.1c). furthermore, whereas untreated cells invaded the collagen in a mixed, but predominantly rounded mode, selumetinib treated cells exhibited a very elongated shape (fig.1c). we next wanted to quantify the invasiveness of selumetinib treated cells. to our surprise, treatment of wm266-4 or a375 cells with selumetinib for 24h resulted in a significant increase in their invasion into 3d fibrillar collagen (fig1.d). this effect was also seen with another mek inhibitor pd184352/ci-1040 (fig.1d), clearly demonstrating that in melanoma cells mek inhibition stimulates increased invasiveness.",pmc3378628,1,10,1,1,11
104,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,hif-1,protein,,hif1a,uniprot,q16665,nucleus,go:0005634,positive,i,expression,,hepatoma,,liver,human,['3609'],nan,nan,"to genetically test the relationship between hif-1 and akt, activated akt was expressed in a hepatoma cell line lacking hif-1 [268]. akt expression was associated with a dramatic increase in tumor size, despite the absence of hif-1 [268]. tumor size was not further increased in cells with reconstituted hif-1 activity, indicating that the effects of akt on tumorigenesis were not limited by the absence of hif-1 [268]. increased tumor size in akt-expressing, hif-deficient cells was associated with vegf secretion and tumor vascularization. thus, akt also has potent, hif-1-independent oncogenic and angiogenic activities [268].",pmc2652403,1,10,1,1,11
3379,tsc1,protein,tumor suppressor gene,tsc1,omim,605284,nucleus,go:0005634,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,negative,i,inhibition,,,,,human,['1977'],nan,nan,"mutations in the tumor suppressor genes tsc1 and tsc2 are associated with a dominant genetic disorder, tuberous sclerosis [393,394]. patients with mutant tsc genes develop benign tumors (hamartomas). in contrast to cowden's patients who have germline mutations at pten where the patients have a high propensity to develop multiple malignancies, tsc patients rarely develop multiple malignant cancers, and if they do develop malignant cancers they are usually either rccs or angiomyolipomas [394]. this has been hypothesized to result from a lack of activation of akt in cells that have mutant tsc1 or tsc2 as mtor activity is expressed at higher levels which results in inhibition of akt, perhaps via the effects of p70s6k on irs1. tsc1 has been shown to be mutated in approximately 15% of urethelial carcinomas (bladder cancers) [394]. rccs are very sensitive to rapamycin and rapalogs.",pmc3660063,1,10,1,1,11
134,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,pras40,protein,,akt1s1,uniprot,o94936,cytoplasm,go:0005737,positive,i,activation,t246,,,,human,['468'],nan,nan,"interestingly, we found that phosphorylation of the akt consensus site t246 in pras40 is moderately reduced in rictor knock down cells (data not shown). this suggests that mtorc2 may activate akt toward pras40. this in turn suggests that mtorc2, via pras40, may be upstream of mtorc1. if mtorc2 is indeed upstream of mtorc1, it might be only under specific conditions or only with regard to particular mtorc1 substrates (other than s6k1), as we and others failed to detect an effect of mtorc2 disruption on s6k1 phosphorylation [14], [15]. the potential regulation of mtorc1 by mtorc2 requires further investigation.",pmc2075366,1,10,1,1,11
168,akt,protein,,akt1,uniprot,p31749,,,mdm2,protein,,mdm2,uniprot,q00987,nucleoplasm,go:0005654,positive,i,inhibition,,,,,,['372'],nan,nan,akt promotes the inhibition of mdm2 through a nucleoplasmic npm/arf complex,pmc4171619,1,10,1,1,11
3107,smad4,protein,monoclonal antibody,smad4,santa cruz biotechnology,b-8,nucleus,go:0005634,smad4,protein,phosphorylated form,smad4,cell signaling technology,14c10,nucleus,go:0005634,positive,d,detection,,,,,human,['92'],nan,nan,"the following antibodies were used in this study for the detection of overexpressed proteins: anti-smad4 monoclonal (santa cruz biotechnology b-8, 1:250), anti-gapdh (cell signaling technology 14c10, 1:7,000), and anti-psmad4gsk318 used at 1:25,000. secondary antibodies used were irdye 800cw donkey anti-rabbit igg (li-cor 926–32213, 1:5,000) and irdye 680rd donkey anti-mouse igg (li-cor 926–68072, 1:5,000).",pmc4845174,1,10,1,1,11
313,arf,protein,,,uniprot,q96kq7,nucleus,go:0005634,mdm2,protein,,mdm2,uniprot,q00987,nucleus,go:0005634,negative,i,inhibition,,,,,,['399'],nan,nan,"the induction of senescence following oncogene activation has been unequivocally demonstrated to require arf [19-22]. however, our data and reports by others [41, 46-48, 81] suggest that the regulation of arf cellular localization is also required for inhibition of mdm2. recent studies have reported that the strength of signal originating from oncogene activation is also important in the arf mediated activation of p53 [88-90]. as arf localization depends on npm oligomerisation this suggests that the strength of a signal must be sufficient to disrupt the equilibrium and release arf, thereby creating a cellular sensor of stress or oncogene activation. we have demonstrated that phosphorylation of ser48 by akt contributes to this process, but additional residues of the n-terminal of npm have been predicted in-silico to regulate oligomerisation [53]. therefore, npm may be able to integrate multiple signals from different kinases in order to control arf localization.",pmc4171619,1,10,1,1,11
321,atm,protein,kinase,atm,uniprot,q13315,cytoplasm,go:0005737,chk2,protein,kinase,chek2,uniprot,o96017,nucleus,go:0005634,positive,d,phosphorylation,t68,,,,human,['3079'],nan,nan,"chk2 is a downstream component of the ddr [8], activated in response to dsbs by atm, which phosphorylates chk2 on t68, triggering its dimerization, auto-phosphorylation and activation. chk2 phosphorylates several substrates, among which p53, brca1, cdc25c, pml, trf2, kap1 and regγ, amplifying the ddr signaling and promoting cell cycle delay, dna repair or apoptosis [7, 8].",pmc4627348,1,10,1,1,11
322,atm,protein,kinase,atm,uniprot,q13315,nucleus,go:0005634,chk2,protein,kinase,chek2,uniprot,o96017,nucleus,go:0005634,positive,d,phosphorylation,thr68,,,,human,['2421'],nan,nan,"key components of the ddr cascade in response to double-strand breaks (dsbs) are the apical kinase atm (ataxia telangiectasia mutated) and its target and effector checkpoint kinase chk2 (2). following dna damage, atm phosphorylates chk2 on thr68, leading to its activation and phosphorylation of several substrates, including p53, hdmx, pml (3), trf2 (3,4) and kap1 (5,6). active chk2 thus amplifies the ddr signal and promotes transient cell cycle arrest to allow dna repair or, in presence of irreparable damages, the induction of apoptosis. the failure of these mechanisms leads to accumulation of genetic alterations, a common feature of cancer cells (7).",pmc4245943,1,10,1,1,11
3048,s6k,protein,,s6k,uniprot,p23443,cytoplasm,go:0005737,irs-1,protein,,irs1,uniprot,p35568,cytoplasm,go:0005737,negative,i,immunoprecipitates,,−/− mefs,,,human,['713'],nan,nan,−/− mefs and rescued by inhibition of s6k. irs-1 immunoprecipitates in unstimulated or insulin-stimulated tsc2,pmc2172316,1,10,1,1,11
2403,p65/rela,protein,subunit,rela,uniprot,q04206,nucleus,go:0005634,nf-κb,complex,,nfkb,fplx,nfkb,nucleus,go:0005634,positive,d,nuclear translocation,,nci-h441,adenocarcinoma,lung,human,['428'],nan,nan,"in our study, nuclear translocation of the p65/rela subunit of nf-κb was significantly increased in moderate dysplasias compared to lower grade lesions. in the carcinomas, there was a reduction of p65/rela nuclear positivity similar to the decreased intensity of phospho-akt staining observed in carcinomas compared to moderate and severe dysplasias. the percentage of cells with positive nuclear staining in carcinomas was also very low compared to moderate and severe dysplasias generally being restricted to isolated foci. in addition to the increased number of biopsies with nuclear staining at higher pathology grades, the overall intensity of cytoplasmic tended to be increased in moderate dysplasias in both the epithelium and stroma compared to normal epithelium (although this difference was not statistically significant in our analysis). in a number of carcinomas, there was intense cytoplasmic staining for p65/rela with an apparent paucity of staining in the nucleus. while these biopsies were scored negative for nuclear staining of p65/rela, it was impossible to discount the possibility that nuclear p65/rela was present in these cells but at levels lower than those observed in the cytoplasm. in the lung adenocarcinoma cell line nci-h441 we have also observed higher levels of p65 immunoreactivity in the cytoplasm than the nucleus although these cells have very high levels of nf-κb activity as measured by reporter gene assays (jwt and mwa, unpublished data). it should also be noted that activation of nf-κb has been reported in lung cancer cells without an increase in nuclear localization [24,54]. in all lesions with positive nuclear staining, a majority of tumor cells did not contain nuclear p65/rela staining. the focal nature of nuclear positivity may reflect the induction of this pathway in a subset of cells that has acquired new genetic or epigenetic changes that activate nf-κb and thus may activate downstream anti-apoptotic pathways.",pmc1325242,1,10,1,1,11
2089,mtorc1,protein,,,uniprot,p42345,cytoplasm,go:0005737,autophagy,process,degradation pathway,,,,,,negative,i,repression,,,cancer,multiple,,['1954'],nan,nan,"mtorc1 is a repressor of autophagy, a lysosome-dependent degradation pathway which allows cells to recycle damaged or superfluous cytoplasmic content, such as lipids, proteins, and organelles [262-280]. as a consequence, cells produce metabolic precursors for macromolecular biosynthesis or atp generation. in cancer cells, autophagy fulfills a dual role, as it has both tumor-promoting and tumor-suppressing properties. functional autophagy prevents necrosis and inflammation, which can lead to genetic instability. however, autophagy might be important for tumor progression by providing energy through its recycling mechanism during unfavorable metabolic circumstances, which are very common in tumors [262-280].",pmc3660063,1,10,1,1,11
765,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,i,phosphorylation,chromatin,hct116,colon cancer,colon,human,['49'],nan,nan,"chk2 can also activate p53 via the phosphorylation of other proteins, such as che-1, strap, hdmx, as described above, and calcineurin binding protein 1 (cabin1). cabin1, in unstressed conditions, keeps p53 in an inactive state on chromatin. in human hct116 colon cancer cells, the induction of dna damage caused chk2 (and atm) to phosphorylate cabin1, promoting its degradation and freeing p53 from inhibition (choi et al., 2013). additionally, in hct116 cells in response to dsbs, chk2 phosphorylated the von hippel–lindau tumor suppressor (vhl, the protein mutated in von hippel–lindau disease, a hereditary cancer syndrome; roe et al., 2011). phosphorylated vhl then associated with an acetylase (either p300 or tip60) and the complex bound p53 at chromatin, leading to p53 transactivation.",pmc4296918,1,10,1,1,11
976,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,egfr (serine/threonine residues),protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,positive,d,autophosphorylation/phosphorylation,c-terminal non-catalytic sequence,,,,,['1391'],nan,nan,"ligand-activated egfr undergoes autophosphorylation on multiple tyrosine residues, most of which are located in the c-terminal non-catalytic sequence; they include y992, y1068, y1086, y1148, and y1173 [7,22–26]. later studies showed that tyrosine residues in egfr could also be phosphorylated by other kinases including src (y845, for detail see below; y891 and y920 [27]; y1045 [28]; y1101 [20]; y1173 [29]). the phosphorylation of serine and threonine residues in egfr was also found: it included t654, t669, s967, s971, s1002, and s1046/s1047 [15,16,30–32]. several lines of evidence indicate that the autophosphorylated tyrosine residues serve as docking sites for a variety of signaling molecules that contain a phosphotyrosine-binding sequence (i.e., src homology 2 or phosphotyrosine-binding domains). on the other hand, serine/threonine phosphorylation acts as a regulatory mechanism for the dimerization, catalytic activity, and/or turnover of the protein [8].",pmc3709701,1,10,1,1,11
986,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,pi3k,protein,,,,,,,positive,i,activation,,,colorectal carcinoma cells,colorectal carcinoma,human,['631'],nan,nan,"another salience of our results is that pp242 treatment leads to the increase of egfr phosphorylation through pi3k-independent pathway in colorectal carcinoma cells. egfr can activate downstream pi3k and erk pathway and thus drives cancer progression [58]. while it remains to be investigated, recent findings that pp242 treatment activates erk pathway in multiple myeloma [59] and pancreatic carcinoma cells [34] suggest the possibility that the mtor kinase inhibitor pp242 may activate erk pathway through the egfr activation. the feedback activation of pi3k-akt and erk pathway undermine the usefulness of the first generation of mtor inhibitors in clinical treatment of cancers. the data presented here in study of colorectal carcinoma, together with the data in studies of myeloma and pancreatic carcinoma cells suggest the presence of feedback activation of erk for the second generation of mtor kinase inhibitors perhaps due the incomplete inhibition of mtorc2 activity and thus raise the concern on whether pp242 is effective in clinical treatment of cancers as single agents.",pmc3750018,1,10,1,1,11
988,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,pi3k,protein,,pik3ca,uniprot,p42336,cytoplasm,go:0005737,positive,i,activation,,,,,,['403'],nan,nan,"the egfr/ras/pi3k/akt pathway has been widely linked with therapeutic resistance of tumors. evidence from in-vitro and in-vivo models suggests that pi3k-akt activation is associated with decreased sensitivity to several chemotherapeutic agents and radiotherapy [3, 7]. additionally, clinical reports highlight the route of resistance to egfr and her2 targeted agents, cetuximab and trastuzumab (herceptin), as being reversible upon pi3k-akt inhibition [98, 99]. our results describe one route of tumor initiation where pathway activation promotes oncogenic activity of p53mut. while this mutational cooperation may contribute to progression, it more importantly highlights the patient cohort where akt inhibitors are most likely to display efficacy.",pmc4171619,1,10,1,1,11
1004,egfr,protein,ptk,egfr,uniprot,p00533,plasma membrane,go:0005886,egfr,protein,ptk,egfr,uniprot,p00533,plasma membrane,go:0005886,positive,d,phosphorylation,y845,c3h10t1/2 fibroblast cells,fibroblast,,human,['1395'],nan,nan,"as described above, elevated levels of src and egfr are often found in a variety of cancer cells [42]. search of the physiological roles played by these two overexpressed ptks has demonstrated a breakthrough finding that they exert synergism in promoting as well as maintaining cancerous cell growth, the main phenomenon implicated in which is y845 phosphorylation of egfr by src [21]. it was shown that the activity of src is required for c3h10t1/2 fibroblast cells overexpressing egfr to undergo cell transformation. as opposed to the case using an nih3t3 cell system ([36], see above), expression of y845f mutant egfr in this cell line leads to a failure of dna synthesis in response to not only egf but also serum and lysophosphatidic acid, indicating that the y845f mutant has a dominant-negative effect on the cellular function of egfr [21]. in this case, however, the y845f mutant is still capable of interacting with src. in addition, it was demonstrated that neither stimulation of the kinase activity of egfr nor that of extracellular signal-regulated kinase (erk)/mitogen-activated protein kinase (mapk) was affected by the expression of the y845f mutant, suggesting that an unknown, non-canonical signaling pathway contributes to the alteration of egfr molecular function, dna synthesis, and malignant cell proliferation under the control of y845 phosphorylation [20,21].",pmc3709701,1,10,1,1,11
1159,erk1/2,protein,,,uniprot,p27361,cytoplasm,go:0005737,erk1/2,protein,,,uniprot,p27361,nucleus,go:0005634,positive,d,phosphorylation,,,lung cancer,lung,human,['486'],nan,nan,"samples from 111 patients were studied by immunohistochemistry. rabbit polyclonal antibodies specific against the dual phosphorylated form of erk1/2 (thr202/tyr204) were used (cell signaling, beverly, ma, usa) at a dilution of 1 : 100 (determined after preliminary serial dilution studies). samples were incubated overnight at 4°c with the primary antibody. immunocytochemical reaction was shown using the envision® tm intensifying kit (dako, carpinteria, ca, usa). positive controls were erk1/2-activated htb58 human lung cancer cells fixed in 10% buffered formalin, which were analysed by immunohistochemistry with the anti-p-erk polyclonal antibody. activation of erk1/2 was achieved by culturing the cells in a medium containing 20% fetal calf serum (fcs) after 16 h of serum deprivation (medium with 0.4% fcs) (data not shown). we also performed western blot analyses of the induction of p-erk after treatment of the cells with two known activating agents, fetal bovine serum (20%) and tpa (100 ng ml−1) (data not shown). negative controls consisted of incubation of serial (positive) lung tumour sections with an unrelated igg rabbit polyclonal antibody. the results of the staining were reviewed independently without knowledge of the clinicopathological data by three of the co-authors (svc, cgc and lmm) who scored the percentage of positive nuclei and/or cytoplasms within tumours and in the normal matching lung at high magnification. average of the scores was registered and no significant divergence was found in the scoring among the observers. serial cuts (3 μm) of a subset of the specimens (five samples that had high percentage of erk1/2 activation and five samples that had no activated erk1/2) were stained using a specific antibody against total erk1/2 (cell signaling, beverly, ma, usa). this experiment was also carried out using a dilution of 1 : 100 as described for the p-erk antibody. the median percentage of p-erk stained cells was 15% and this was chosen as the cutoff value. a score of 15% or higher was considered positive. intensity of the staining was also registered and evaluated in a semiquantitative way but the intensity of the staining was fairly similar from specimen to specimen, and its inclusion in the statistical analysis did not modify the calculations based on extension alone; therefore, it will not be reported here.",pmc2409626,1,10,1,1,11
1675,jnk,protein,,mapk8,uniprot,q27754,cytoplasm,go:0005737,c-jun,protein,,jun,uniprot,p05412,nucleus,go:0005634,positive,i,increase in levels,,,unknown,unknown,unknown,['193'],nan,nan,the continued increase in p-c-jun levels hours after jnk activity had diminished,pmc3084876,1,10,1,1,11
2036,mtor,protein,,,uniprot,p42345,cytoplasm,go:0005737,p70s6k,protein,,rps6kb1,uniprot,p23443,cytoplasm,go:0005737,positive,i,phosphorylation,,,epithelial,bladder,human,['2806'],nan,nan,"we previously reported that activating the mtor pathway, such as phosphorylating p70s6k, is related to high recurrence and disease progression in non-muscle invasive urca of the bladder.8 several studies have revealed that the pi3k/akt/mtor pathway is largely responsible for promoting cell growth in non-muscle invasive lg-urca of the bladder.910 therefore, we investigated whether inhibiting phosphorylated p70s6k suppresses the proliferation and growth of non-muscle invasive lg-urca in vitro models and whether phosphorylated p70s6k is a predictive biomarker for recurrence and progression of noninvasive lg-urca of the bladder in a patient model.",pmc4104092,1,10,1,1,11
70,akt,protein,kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,mtor,protein,kinase,mtor,uniprot,p42345,cytoplasm,go:0005737,positive,i,phosphorylation,s473,,colon cancer,,human,['1264'],nan,nan,"akt has been established as a major signaling node in numerous pathologies including cancer 28. this is rooted in the elevated akt levels found in tumor tissue eliciting inhibitory effects on proapoptotic signaling events, activating cell proliferation, and cell growth 29. akt is a serine/threonine kinase whose actions are brought about through a variety of phosphorylation sites. initially akt is partially activated via the igf-1r/pi3k signaling pathway by pdk1 at t309, however it is s473 phosphorylation by mtor and specifically the mtorc2 complex that results in maximal activation. upon phosphorylation of s473, akt can activate or inhibit numerous signaling molecules in colon cancer 30, 31. of growing importance are the signaling molecule mtor and the signaling cascade it regulates via two very different complexes, mtorc1 and mtorc2. akt has been shown to phosphorylate mtor via pras40, a component of mtorc1. further downstream, mtor phosphorylates p70 s6 kinase (t389), a regulator of ribosomal protein s6 (rps6) responsible for mrna translation, and has been proposed to signal via 14-3-3 (tyrosine 3-monooxygenase), a required protein in raf signaling, to inhibit irs-1 in a negative feedback loop 32.",pmc3187934,1,10,1,1,11
